

# Mitochondria-associated Membranes (MAMs): Composition, Molecular Mechanisms and Physiopathological Implications

Carlotta Giorgi<sup>1</sup>, Sonia Missiroli<sup>1</sup>, Simone Patergnani<sup>1</sup>, Jerzy Duszynski<sup>2</sup>, Mariusz R Wieckowski<sup>2,3</sup>, and Paolo Pinton<sup>1, 3\*</sup>

<sup>1</sup> Department of Morphology, Surgery and Experimental Medicine. Section of Pathology, Oncology and Experimental Biology. Laboratory for Technologies of Advanced Therapies (LTTA). University of Ferrara, Ferrara, Italy.

<sup>2</sup>Department of Biochemistry, Nencki Institute of Experimental Biology; Warsaw, Poland.

<sup>3</sup>These authors share senior co-authorship.

\* Corresponding author:  
Paolo Pinton, PhD  
Email: [pnp@unife.it](mailto:pnp@unife.it)

## **Abstract**

**Significance:** in all cells, the endoplasmic reticulum (ER) and mitochondria are physically connected to form junctions termed mitochondria-associated membranes (MAMs). This subcellular compartment is under intense investigation because it represents a “hot spot” for the intracellular signaling of important pathways, including the synthesis of cholesterol and phospholipids, calcium homeostasis and reactive oxygen species (ROS) generation and activity.

**Recent advances:** the advanced methods currently used to study this fascinating intracellular microdomain in detail have enabled the identification of the molecular composition of MAMs and their involvement within different physiopathological contexts.

**Critical issues:** here we review the knowledge regarding i) MAMs composition in terms of protein composition, ii) the relationship between MAMs and ROS, iii) the involvement of MAMs in cell death programs with particular emphasis within the tumor context, iv) the emerging role of MAMs during inflammation and v) the key role of MAMs alterations in selected neurological disorders. **Future directions:** whether alterations in MAMs represent a response to the disease pathogenesis or directly contribute to the disease has not yet been unequivocally established. In any case, the signaling at the MAMs represent a promising pharmacological target for several important human diseases.

**Key words:** MAMs, MAM, Calcium ( $\text{Ca}^{2+}$ ), cell death, apoptosis, autophagy, ROS, inflammation, endoplasmic reticulum, cancer, neurological disorders

## I. Introduction and MAMs Composition

The intracellular mobility of biological macromolecules and organelles is highly restricted by the high viscosity of the cytosol (87) due to the extreme crowding of intracellular components (46). *In vivo*, nearly all biological macromolecules and other intracellular structures exist, at least transiently, as components of structural and functional complexes (1). This restricted mobility also influences the strength of interactions between various intracellular components. The attractive interactions between components, such as the high affinity of interacting protein structures, represent an additional factor influencing this strength. The direct interactions between mitochondria and the ER within the cell have been extensively studied both functionally and structurally. The first approach involved studies on the direct exchange of ions and metabolites between the organelles, particularly that of  $\text{Ca}^{2+}$  ions (142,154). The close apposition of mitochondria to the ER was found to account for the selective transmission of physiological and pathological  $\text{Ca}^{2+}$  signals directly from the ER to the mitochondria (60,145). The second approach involved microscopic visualization of the interactions or isolation of the interacting regions of the organelles and identification of the proteins or lipids present at the sites of interaction. The mutual affinities between these molecules strengthen the interaction between intracellular components, enhancing the half-life of their interaction. When this strength exceeds a certain level and escapes the “kiss and run” formula, it is possible to isolate the interacting fragments of the interacting organelles. MAMs (61,104,179), ER-mitochondria encounter structures (ERMESs) (96,97) and plasma membrane-associated membranes (PAMs) (168) represent the best known examples of these preparations.

Among these preparations, MAMs (Fig. 1 and Fig. 2) are the best characterized. The first reports of the direct association of mitochondria and the ER date from the late 1950s (31), and this type of preparation has been subsequently characterized by numerous groups [for recent reviews, see (94,114,125)]. An isolated MAMs fraction is composed of membrane fragments from both the ER and the outer mitochondrial membrane (OMM) that had been in close contact at the time of cellular subfractionation. More recently, the ER portion of the MAMs fraction has been regarded as a detergent-resistant lipid raft (5,52).

The contact sites between mitochondria and the ER are dynamic structures that are sensitive to the physiological conditions of the cell. This dynamic nature results in a transient and highly variable MAMs composition. The variety of roles played by the MAMs fraction that have been described is related to their unique lipid and protein composition. The studies performed in the last decade that have identified the molecular components of the MAMs fraction have demonstrated that this fraction may contain numerous proteins (more than 75 according to Raturi and Simmen (149), more than 1,000 according to Poston and colleagues (147)). From this protein composition, it was deduced that MAMs are crucial for numerous cellular processes, including protein sorting [as indicated by the presence of phosphofurin acidic cluster sorting protein 2 (PACS-2)], inflammation [as indicated by the presence of the following inflammasome components: NACHT, LRR and PYD domains-containing protein 3 (NALP3), adaptor ASC and thioredoxin-interacting protein (TXNIP)], ER stress [e.g., 75-kDa glucose-regulated protein (GRP75) and ER resident protein 44 (ERp44)], Ca<sup>2+</sup> handling [e.g., the inositol 1,4,5-trisphosphate receptor (IP3R), ryanodine receptor, sigma-1 receptor (Sig1R), and promyelocytic leukemia protein (PML)], mitochondrial contact sites [e.g.,

the voltage-dependent anion channel (VDAC) and adenine nucleotide translocase (ANT)], lipid synthesis and trafficking [e.g., PSS-1 and PSS-2, serine active site containing 1 (SERAC1), FAACL1 and FAACL4, acyl-CoA desaturase, fatty acid transport protein 4 (FATP4), phosphatidylethanolamine *N*-methyltransferase 2 (PEMT2) and several other proteins; for additional details, see (158)], protein folding [e.g., calnexin (CNX)], apoptosis [e.g., Bcl-2 and HCLS1-binding protein 3] and modulation of mitochondrial morphology [mitochondria-shaping proteins and chaperone proteins (mitofusins 1 and 2; MFN1 and MFN2, respectively)]. Moreover, MAMs are the predominant subcellular location for  $\gamma$ -secretase activity and for presenilin-1 (PS1) and presenilin-2 (PS2), two proteins that, when mutated, cause familial Alzheimer's disease (FAD) (4,5) as discussed in detail below. The ER-mitochondrial crosstalk can also be affected by several viral proteins such as human cytomegalovirus vMIA and the p7 and NS5B proteins of hepatitis C virus, which are also targeted to MAMs. Moreover, it has been found that the tumor suppressor PML can modulate the ER-mitochondria  $\text{Ca}^{2+}$  cross talk by its presence in MAMs (144). Additionally, p66Shc, which is a cytosolic adaptor protein that is involved in the cellular response to oxidative stress when phosphorylated at Ser36, has also been identified at the sites of mitochondria-ER association (61,101). Taking into account that the MAMs fraction contains numerous crucial proteins, as previously mentioned, the involvement of MAMs-mediated disturbances in the pathogenesis of a variety of diseases is not surprising (149). However, the localization of some proteins in the MAMs fraction and the extent of their enrichment remain under debate, and at times, the relationship of these proteins to the MAMs fraction is unclear; see the review by Raturi and Simmen (149).

## II. Relationship Between MAMs and ROS

An interesting example of a MAMs-resident ROS-generating protein is the p66Shc protein. Under physiological conditions, this growth factor adaptor protein (which, in addition to p52Shc and p46Shc, belongs to the ShcA family) is involved in signal transduction via the RAS protein. However, under oxidative stress (exogenous and intracellular) p66Shc can participate in the signaling pathway leading to apoptosis. This dual nature of p66Shc arises from the different (tyrosine and serine) phosphorylation sites within this protein. All ShcA proteins possess a similar domain structure; however, p66Shc (which is a product of an alternatively spliced transcript from the SHC1 gene) contains an additional N-terminal proline-rich collagen-homology domain (CH2) containing a serine phosphorylation site (Ser36) that is important for the aforementioned “proapoptotic” properties (40,170) as well as a functional region (CCB) that is responsible for its interaction with cytochrome c (63). As observed for p52Shc and p46Shc, when phosphorylated, p66Shc has been found to bind the Grb2/SOS complex and, in this way, competes with p52Shc for binding to Grb2. This finding suggests that p66Shc can function as a dominant negative regulator of the RAS-mediated signaling pathway (122,131). Under oxidative stress caused by UV radiation or H<sub>2</sub>O<sub>2</sub> treatment, p66Shc can be phosphorylated at Ser36 by one of the serine-threonine kinases (protein kinase C  $\beta$  (PKC  $\beta$ ) (59), c-Jun N-terminal kinase (JNK), or extracellular signal-regulated kinase (ERK)) (79,100,146). Moreover, phosphorylation of p66Shc at Ser36 can be mediated by apoptosis signal-regulating kinase 1 (ASK1)-JNK phosphorylation (110). This phosphorylation initiates the following cascade of events: a) isomerization of

Ser36-phosphorylated p66Shc by the prolyl isomerase Pin1, b) dephosphorylation of Ser36-P-p66Shc by phosphatase A2 (PP2A) (10) and c) translocation of p66Shc to the mitochondria and/or MAMs fraction, where it participates in ROS production (64,146) (Fig.3). Additional details on the “nature” of p66Shc can be found in the comprehensive review by Migliaccio et al. (121). It should also be noted that the ROS-sensitive fluorescent probes used in studies describing the ability of MAMs-resident proteins to produce different ROS unfortunately cannot precisely detect reactive oxygen species. For example, the *CM-H<sub>2</sub>DCF* probe used for the measurement of hydrogen peroxide can also detect other ROS, due to the fact that the oxidation of H<sub>2</sub>DCF to DCF is a two-step process: first, the DCF radical is formed, and it is then (second step) oxidized to DCF in a reaction with molecular oxygen (163,176). Unfortunately, the first step of H<sub>2</sub>DCF oxidation can be mediated by various radical species, such as hydroxyl radicals, carbonate radicals and nitrogen dioxide, as well as by thiyl radicals resulting from thiol oxidation (42,71,88,181,182). Moreover, alteration of the fluorescent probe signal can be caused by superoxide radicals (formed in the second step of H<sub>2</sub>DCF oxidation), which can be dismutated to hydrogen peroxide and cause self-amplification of the signal (67,128). Similarly, *dihydroethidium (DHE)*, and MitoSOX, which are used for the measurement of superoxide, are also not completely specific. For example, DHE and MitoSOX can undergo unspecific oxidation by ONOO<sup>-</sup> or •OH into ethidium or mito-ethidium, respectively (88). For this reason, even if the exact form of ROS (e.g., superoxide or H<sub>2</sub>O<sub>2</sub>) is stated in the text of the original paper commented upon in our review, other reactive oxygen species should also be taken into consideration due to the constraints imposed by probe chemistry.

The first reports addressing the cytosolic localization of p66Shc indicated that it could also be localized in the mitochondrial matrix. Moreover, Orsini et al. found that p66Shc can interact with mitochondrial Hsp70 and regulate  $\Psi_m$  (mitochondrial membrane potential) (133). Subsequent studies have revealed that mitochondrial p66Shc is present in the mitochondrial intermembrane space (IMS), where it interacts with cytochrome *c* and, as a redox enzyme, produces  $H_2O_2$  (63). However, the determination that nearly 35% of the mitochondrial p66Shc localizes within the mitochondrial intermembrane space (63) appears to be an overestimation (101,179). Regarding this model, Gertz *et al.* have proposed that the N-terminus of p66Shc forms a redox module and serves as a thiol-based redox sensor. Under oxidizing conditions, p66Shc can be “activated” due to the formation of two disulfide bonds, resulting in the reversible tetramerization of p66Shc. In contrast, under normal conditions, glutathione and thioredoxins protect against p66Shc tetramerization by reducing potentially formed disulfide bonds and, in this way, inactivate the proapoptotic properties of p66Shc (56).

Direct involvement of p66Shc in mitochondrial ROS production has been repeatedly described by several groups (37,64,102,103,146). However, it remains unclear whether p66Shc can translocate across the OMM and resides in the IMS, where it can interact with cytochrome *c* (63), or if it binds to the OMM from the cytosolic side (101). In the model in which p66Shc is localized in the IMS p66Shc has been proposed to interact with cytochrome *c* (due to the CCB domain present in p66Shc) and transfers electrons from cytochrome *c* to molecular oxygen, which results in  $H_2O_2$  formation. p66Shc present in the MAMs fraction can interact with an as yet unidentified outer mitochondrial membrane protein and, thus, can participate in ROS production (Fig.3). Our studies have shown that p66Shc can be found not only in the cytosol and MAMs



(179), but also in the PAM fraction (101). Interestingly, the level of p66Shc in the MAMs fraction increases in an age-dependent manner, corresponding well to mitochondrial H<sub>2</sub>O<sub>2</sub> production, which has been found to increase with age (101). Lebiezinska et al. performed studies on fibroblasts from patients with diagnosed mitochondrial disorders and demonstrated that p66Shc can also be phosphorylated at Ser36 in the event of intracellular oxidative stress caused by mitochondrial dysfunction (102,103). In the case of these studies, it is very difficult to distinguish whether the “activated” p66Shc pathway in fibroblasts from patients participates in superoxide (O<sub>2</sub><sup>-</sup>) or H<sub>2</sub>O<sub>2</sub> production. Admittedly, the administration of hispidin (an inhibitor of PKCβ phosphorylation of p66Shc) decreases cytosolic and mitochondrial O<sub>2</sub><sup>-</sup> levels in these cells, indicating that p66Shc may be involved in the production of this type of ROS. However, hispidin also causes an increase in the levels of cytosolic and mitochondrial dismutases (SOD1 and SOD2), which are enzymes catalyzing the reduction of superoxide anions to H<sub>2</sub>O<sub>2</sub>. Therefore, a decrease in the O<sub>2</sub><sup>-</sup> level following hispidin treatment can be caused not only by the inhibition of p66Shc Ser36 phosphorylation but may also be SOD1 and SOD2 specific. ROS production by p66Shc appears to be a specialized function whereby electrons are removed from the ETC to catalyze the partial reduction of molecular oxygen (63). The redox activity of p66Shc accounts for the decrease in ROS levels observed in p66Shc knockout cells (121) and is also responsible for an altered mitochondrial metabolism under basal conditions that is characterized by lower oxygen consumption (129).

Interestingly, the connection between p66Shc and ROS seems to have significant physiological relevance in the case of hypertension. It appears that p66shc mediates

hypertension-associated, cyclic stretch-dependent, endothelial damage and that in stressed cells, activation of integrin  $\alpha 5 \beta 1$  and c-Jun N-terminal kinase enhances the phosphorylation p66shc at Ser36 and, thus, ROS production (166). The results of these experiments can be extrapolated to an organismal level as well. It has been demonstrated that in mice lacking p66shc, age-related and hyperglycemia-induced endothelial dysfunctions (24,32,65,93) as well as the extent of atherosclerosis (126) are diminished.

Additional examples of proteins that can produce ROS and that are localized in the MAMs fraction include Ero1-L  $\alpha$  (which is present in several tissues and most cell types) and Ero1-L  $\beta$  (which is abundant in cells with a high secretory capacity) (2,47,149). Although Ero1-L  $\alpha$  is a luminal ER oxidoreductase, it presumably binds to the ER membranes in regions involved in MAMs formation, resulting in greater than 75% of Ero1-L $\alpha$  localization in the MAMs fraction (58). Ero1-L $\alpha$ , in addition to protein disulfideisomerase (PDI), is responsible for the formation of disulfide bonds and, hence, plays an essential role in protein folding (21,45). Enyedi et al. have shown that the activity of Ero1-L $\alpha$  results in significant H<sub>2</sub>O<sub>2</sub> formation in the ER. Briefly, oxidative protein folding consists of two major steps: a) the FAD-bound Ero1 protein oxidizes the PDI (e.g., ERp44 or ERp57) and b) PDI subsequently catalyzes the formation of disulfide bonds within newly synthesized/folding proteins (3). Ero1-L $\alpha$  uses oxygen, which is finally reduced to H<sub>2</sub>O<sub>2</sub> as the electron acceptor upon the oxidation of PDI (74). Studies performed on yeast have indicated that greater than 25% of the ROS produced during protein synthesis/folding is related to yeast homolog Ero1p activity (172). The interplay between Ero1-L $\alpha$  and ERp44, which is an ER luminal chaperone protein (with

thioredoxin activity) that is also present in the MAMs fraction, is responsible for the regulation of  $\text{Ca}^{2+}$  release from the ER via IP3R1. Ero1-L  $\alpha$  in the ER-mitochondrial hot spots interacts with IP3R1, oxidizing it to potentiate the release of  $\text{Ca}^{2+}$  during ER stress (2). Interestingly, hypoxic conditions result in the complete relocation of Ero1-L  $\alpha$  from MAMs, indicating that its intracellular localization depends on oxidizing conditions (58). Moreover, the ability of Ero1-L $\alpha$  to modulate ER-mitochondria  $\text{Ca}^{2+}$  communication may substantially affect the induction of apoptosis (40,169). In contrast, ERp44 interactions with IP3R1 under reducing ER conditions inhibit  $\text{Ca}^{2+}$  transfer to the mitochondria (76); however, the oxidation of IP3R1 by Ero1-L $\alpha$  is accompanied by ERp44 dissociation from the complex with IP3R1, which enables its full activation (2,109) (Fig.3).

Additional details on these topics can be found in the following reviews (149,165).

### **III. MAMs in Cell Death Pathways**

Several studies have highlighted and broadened the functional roles of MAMs in a variety of cellular processes, from lipid synthesis/transport,  $\text{Ca}^{2+}$ -signaling and ER stress to mitochondrial morphology.

In addition to these roles, MAMs play a key role in the initiation and amplification of cell death. In the following sections, we will illustrate how these contact sites serve as signaling platforms that are capable of determining cellular life and death decisions through the regulation of programmed cell death events.

#### **A. Apoptosis**

In the mitochondrial pathway of apoptosis, stress signals induce mitochondrial outer

membrane permeabilization (MMP), which results in permeabilization of the outer mitochondrial membrane (OMM). MMP then facilitates the release of several proteins that normally reside in the mitochondrial intermembrane and intracristal space. These proteins include cytochrome C (cyt-C), apoptosis-inducing factor (AIF) and Smac/DIABLO. Finally, these proteins trigger or facilitate the formation of a caspase-activating complex, the apoptosome, which results in the activation of effector caspases (66). It is therefore clear that one of the key steps of mitochondrial apoptosis is the permeabilization of the OMM. This event is highly regulated by members of the BCL-2 family, particularly through the activity of BAX, BAK and BID. Under normal conditions, the proapoptotic protein BAK is situated in the cytosolic compartment. Upon apoptosis induction, BAX inserts into the OMM, where it associates with BAK or BID. Such complexes stimulate MMP and the release of cyt-C by forming pores in the OMM. Nevertheless, how this molecular opening induced by BAX/BAK/BID occurs is still controversial. A first putative mechanism suggested the cooperation of BAX with other proteins to form and open a pore in the inner membrane (the so-called mPTP, permeability transition pore complex) allowing water and proteins up to ~1.5 kD to pass through (98).

The mPTP is a multiprotein complex that forms at the junctions between the inner and outer mitochondrial membranes. The present mPTP model is built around the F1/Fo ATP-synthase and is composed of several elements, including ANT, VDAC, BAX and BAK (12,14,15).

Opening the pore results in matrix swelling and OMM disruption, which in turn, promote the release of proteins from the IMS.

An alternative model of MMP was proposed, which did not indicate a key role for the

PTP. This mechanism is regulated by BCL-2 proteins, which act directly on the OMM. For example, it was found that anti-apoptotic BCL-2 family members work to block the MMP, while proapoptotic members can act to activate BAK/BAX/BID or interfere with anti-apoptotic BCL-2 family members (48,99).

Other studies suggest a critical role of VDAC in the MMP and apoptosis (162). Initially, the overexpression of VDAC leads to apoptosis in a variety of cell types (186). In addition, several work address the molecular pathway involving VDAC. In fact, under physiological conditions, antiapoptotic BCL-2 members interact with VDAC and regulate its function, which is to shuttle ATP from the mitochondrial matrix to the cytoplasm (73). However, the scenario is not actually quite so simple: recent evidence shows that the contribution of VDAC to cell death can be isoform and stimulus dependent. Accordingly, it has been found that VDAC1 silencing promotes apoptosis, whereas silencing of VDAC2 has the opposite effect (38).

MMP is not the only crucial event in apoptosis. There is also a major change in the membrane potential (in the plasma membrane potential [ $\Psi_{pm}$ ] and the mitochondrial transmembrane potential [ $\Psi_m$ ]) accompanying MMP. Under normal conditions, the  $K^+$  concentration is much higher in the cytosol than in the extracellular fluid. A continuous, low  $K^+$  efflux, via  $K^+$ -channels, is essential for the maintenance of  $\Psi_{pm}$ , which is vital for ion and volume homeostasis. It has been reported that during mitochondrial swelling and MMP,  $\Psi_{pm}$  collapses, resulting in dissipation of intracellular [ $K^+$ ], cell shrinkage, DNA fragmentation and loss of membrane asymmetry, with aberrant exposure of phosphatidylserine residues on the plasma membrane surface (35). Thus, a gross perturbation of  $\Psi_{pm}$  appears to occur in the post-mitochondrial stage of apoptosis.

$\Psi_m$  also contributes to mitochondrial apoptosis. A prominent dissipation of  $\Psi_m$  takes

place in the early stage of the apoptotic process after the opening of the PTP. Nevertheless, studies suggest that loss of  $\Psi_m$  could be a consequence of the apoptotic-signaling pathway. For example, during the etoposide-induced apoptosis of L929 fibroblasts, loss of  $\Psi_m$  occurs as a late event following nuclear alterations and BAX translocation to the mitochondria (91). Moreover, it has been suggested that loss of  $\Psi_m$  is not required for cyt-C release, but only for the release of AIF (112). Considering these remarks, it is clear that dissipation of  $\Psi_m$  is a classic feature of apoptosis, but its effective role in this pathway remains to be addressed.

#### **Ai) Cardiolipin (CL)**

To play crucial roles in cellular bioenergetics and cell survival, mitochondria require the correct import of a large number of proteins from the cytosol. Lipids play a key role in this “mitochondrial protein sorting”. Of the mitochondrial lipids, the dimeric phospholipid CL is characteristic of this organelle, and it is responsible for the stability of several IMM protein complexes (33). Reduced levels of CL induce a collapse of  $\Psi_m$  with consequent blocking of the  $\Psi_m$ -dependent protein translocation into mitochondria. Moreover, during apoptosis, CL is redistributed between the IMM and the OMM, and its oxidation induces the release of proapoptotic factors (53,86). Although the molecular mechanism of CL translocation remains elusive, MAMs have been proposed to play a key role in CL movement. In demonstration of this theory, the state and efficiency of MAMs are prime determinants for CL transfer and recruitment to the OMM (78,152) (Fig.4).

#### **Aii) Mitochondrial Network**

The shape of the mitochondrial network is also important to the functioning and health of

the cell. During apoptosis, the mitochondrial network undergoes dramatic rearrangements, and it is generally accepted that it collapses into small spherical structures in response to apoptotic stimuli.

Furthermore, as discussed above, mitochondrial dynamics and morphology are modulated by a correct assemblage of ER-mitochondria contacts. In wild-type cells, during apoptosis, mitochondrial fission facilitates mitochondrial fragmentation, the collapse of  $\Psi_m$  and the release of IMS-stored apoptogenic factors. For example, inhibition of fission through DRP1 RNA interference retards the release of cyt-C from the IMS (107). Consistent with these data, DRP1-KO-derived MEFs display a delay in cyt-C release and retardation of caspase activation (81), and RNA interference targeting MFF induces mitochondrial elongation, with a consequent delay in cyt-C release and blocking of the apoptotic program.

Taken together, these data suggest an important role of fission-related proteins during the progression of the apoptotic program. Following the induction of apoptosis, the fission protein DRP1 translocates to the OMM, with consequent augmentation of mitochondrial fragmentation. Indeed, it has been reported that during apoptosis cytosolic BAX/BAK proteins travel to the OMM and interact with DRP1 and MFN2. As a result, these BCL-2 member proteins promote SUMO modifications of DRP1, which stably associates with the OMM (18,177). In addition, BAX/BAK induce tBID activation, which is correlated with blocking of mitochondrial fusion, most likely through inhibition of the mitofusin protein MFN-2 (90). The activation of fusion proteins (such as MFN-1 /-2 and OPA1) that are indispensable for the maintenance of normal mitochondrial morphology and calcium uptake by mitochondria, antagonizes apoptosis progression (51).

Accordingly, inhibition of OPA1-mediated fusion through RNA interference leads to

fragmentation of the mitochondrial network, concomitant with the dissipation of the mitochondrial membrane potential. As a consequence of these events, cyt-C is released, and executioner caspases are activated (28,132).

The apoptotic program is also promoted by depletion of PACS2. Indeed, the absence of PACS-2 induces the caspase-dependent cleavage of BAP31 to yield the pro-apoptotic fragment p20, causing mitochondria to fragment and uncouple from the ER (164).

Overall, these findings indicate that disruption of the apposition of mitochondria with the ER and the consequent increase in mitochondrial fragmentation are functionally linked to apoptosis induction.

### **Aiii) Calcium ( $\text{Ca}^{2+}$ )**

$\text{Ca}^{2+}$  homeostasis is fundamental to numerous cellular mechanisms, including cell death. Elevation of the intracellular  $\text{Ca}^{2+}$  concentration is dependent on either  $\text{Ca}^{2+}$  influx from the extracellular space through the plasma membrane, or  $\text{Ca}^{2+}$  release from intracellular  $\text{Ca}^{2+}$  stores, such as those in the ER. The mitochondria are equally important for  $\text{Ca}^{2+}$  signaling. Different works have demonstrated that  $\text{Ca}^{2+}$  release from the ER results in cytosolic  $\text{Ca}^{2+}$  increases that are paralleled by similar or even increased cycles of mitochondrial  $\text{Ca}^{2+}$  uptake (11,116).

This unique characteristic of the mitochondria is principally due to the large electrochemical gradient  $\Psi_m$  and to the existence of MAMs. As describe above, the close apposition of the mitochondria and ER creates  $\text{Ca}^{2+}$  hotspots, which have been found to play pivotal roles in several cellular functions, including the highly efficient transmission of  $\text{Ca}^{2+}$  from the ER to the adjacent mitochondrial network to stimulate oxidative metabolism. Apoptosis also is intimately connected to the regulation of  $\text{Ca}^{2+}$



handling promoted by MAMs. An excess of  $\text{Ca}^{2+}$  flows out of the ER into mitochondria via IP3 receptors (which present at high levels in the MAMs compartment) and promotes the apoptotic program (142). For example, several studies have correlated MAMs with increased  $\text{Ca}^{2+}$  transfer in sensitization to apoptosis. For example, the  $\text{Ca}^{2+}$  fluxes into mitochondria induce the oligomerization and activation of BAX, which promotes the permeabilization of the OMM and, ultimately, the release of pro-apoptotic factors into the cytosol. Other proteins that link the ER to mitochondria have been found to exert control over pro-apoptotic  $\text{Ca}^{2+}$  fluxes in stressed cells.

A growing body of research highlights the key role of the oncogene H-RAS in the maintenance of tumor survival and proliferation. Although the clear molecular mechanisms underlying these processes are not well established, a recent study illustrated a direct link between  $\text{Ca}^{2+}$  regulation and HRAS-driven transformation. In this work, Rimessi et al. identified HRAS localized to the MAMs compartment, suggesting the possibility that this localization may serve as a strategic point to regulate the transmission of  $\text{Ca}^{2+}$  from the ER to mitochondria. Indeed, after the induction of oncogenic HRAS, global intracellular  $\text{Ca}^{2+}$  perturbation accompanied by a dysfunction of mitochondrial physiology has been observed (153).

PTEN (protein phosphatase and tensin homolog deleted on chromosome 10), a tumor suppressor that downregulates AKT and localizes to the MAMs compartment, was recently shown to be able to interact with the AKT/IP3R complex (11), leading to a reduction of its phosphorylation and an increase in  $\text{Ca}^{2+}$  release. The tumor suppressor PML also modulates the ER-mitochondria  $\text{Ca}^{2+}$  signaling platform. This protein was found to localize to the ER and MAMs, where it interact with IP3R3, regulating the ER-mitochondria  $\text{Ca}^{2+}$  flux and apoptosis. Furthermore, using PML-KO derived MEFs and a

PML chimera that exclusively localizes to the outer surface of the ER (erPML), our laboratory demonstrated that PML also acts as a suppressor of other oncogenic pathways. Indeed, loss of PML promotes a reduction of PP2A activity at the ER and an increase of AKT activity. Consequently, the hyper-phosphorylation of IP3Rs mediated by AKT inhibits ER  $\text{Ca}^{2+}$  release and causes the cell to be less sensitive to  $\text{Ca}^{2+}$ -mediated apoptotic stimulation (62).

Other central players in the ER-mitochondria  $\text{Ca}^{2+}$  flux include a series of chaperones and oxidoreductase, which also localize to the ER/MAMs compartment. ERp44, an ER luminal protein of the thioredoxin family, was found to directly interact with IP3R1, inhibiting its channel activity. Specifically, Higo et al. demonstrated that ERp44 directly inhibits the channel activity of IP3R1 in a pH-, redox state-, and  $[\text{Ca}^{2+}]_{\text{ER}}$ -dependent manner (76). Furthermore, in this study, it was demonstrated that ERp44 also reinforces the ERO1 $\alpha$ /oxidoreductase system. ERO1- $\alpha$  is an enzyme that modulates the activity of PDI (protein disulfide isomerase). ERO1- $\alpha$  localizes to the MAMs and ER, where can interact with and control the activity of HIF1- $\alpha$ , modulating the hypoxic response to disulfide bond formation (120). Based on these observations, the reported intimate relationship between ERp44 and ERO1- $\alpha$  could play a key role in the modulation of IP3R-dependent calcium signaling and, thus, in the regulation of the apoptotic program.

It is clear that the release of  $\text{Ca}^{2+}$  from ER stores is an essential component of cell survival processes, particularly apoptosis. Upon release from the ER,  $\text{Ca}^{2+}$  is taken up by mitochondria through the mitochondrial calcium channel uniporter (MCU), which together with its regulators (MICU1, MICU2, MCUB, EMRE, MCUR1 and miR-25), constitutes the mitochondrial calcium uniporter complex (113,115). Next, the  $\text{Ca}^{2+}$  flux

promotes apoptosis induction through the activation of the mPTP which in turn promotes cyt-C release and caspase activation. As described above, the mPTP is composed of several components, including proteins localized at MAMs (12). Based on this observation and considering the key role of the mPTP in cell survival, it is possible to predict a direct and novel role of ER-mitochondria apposition in mPTP regulation and, thus, in the onset of apoptosis. Several findings suggest the existence of this intimate relationship. mPTP opening is an important event in cardiomyocyte cell death during ischemia-reperfusion (I/R). Additionally, peroxidation of CL by ROS in the presence of  $\text{Ca}^{2+}$  induces mitochondrial permeability transition and cyt-C release in rat heart mitochondria. Thus, increased levels of peroxidized CL and  $\text{Ca}^{2+}$  might lead to the opening of the mPTP. Furthermore, these effects were not observed for non-oxidized CL and were inhibited by cyclosporin A and bongkreikic acid (138,143). Considering that MAMs are prime determinants of CL homeostasis and  $\text{Ca}^{2+}$  handling, it is possible that these membranes play an active role in the regulation of mPTP opening during I/R.

Other indications of the existence of this relationship might be found by considering p66Shc. As described above, p66Shc is a MAMs protein that is strongly regulated by ROS and is involved in  $\text{Ca}^{2+}$  handling. Once activated, p66Shc oxidizes reduced cyt-C and catalyzes the reduction of  $\text{O}_2$  to  $\text{H}_2\text{O}_2$  using electrons from the respiratory chain. The generated  $\text{H}_2\text{O}_2$  leads to mPTP opening and consequent caspase activation and apoptosis (64).

The ER is not only one of the main sites of intracellular  $\text{Ca}^{2+}$  storage in the cell; it is also considered the primary site for the synthesis and folding of proteins for the entire cell. When the capacity of the ER machinery to fold proteins becomes inadequate, the cell enters into a dangerous state, known as “ER stress”. When ER stress becomes too

severe and the dedicated signaling pathways (such as UPR) cannot alleviate this condition, a lethal signal may be turned on, giving rise to cell death, usually in form of apoptosis.

Upon ER stress three sensor proteins of UPR-system (ATF6, PERK and IRE1- $\alpha$ ) generally stimulate an increase of ER and a gain of function of chaperone activity. Consequently, the ER morphology undergoes considerably changes, and the ER-mitochondria contact sites become stronger and closer. This increased coupling results in major oxygen consumption, a stronger reductive capacity and augmented  $\text{Ca}^{2+}$  transfer. This increase in mitochondrial activity is observed only where the reticular and mitochondrial networks are redistributed. Overall, these findings suggest that the increased juxtaposition between the ER and mitochondria observed during ER stress could contribute favorably to cellular adaption to stressful conditions (17).

Nevertheless, these dependent ER stress sensor proteins can modulate the transmission of signals between the ER and mitochondria in a UPR-independent manner. For example, ablation of the protein PERK, which was recently discovered to be enriched in the MAMs fraction, in addition to the ER compartment, promotes perturbations of ER-mitochondria contact sites and reduces apoptotic activity in response to agents inducing ROS production,  $\text{Ca}^{2+}$  transfer and ER stress. Collectively, these data reveal that a conserved MAMs structure is indispensable for transmitting  $\text{Ca}^{2+}$  as well as ROS-mediated signals to the mitochondria following ROS-based ER stress (174). Accordingly, cells lacking MFN2 exposed to ER stress display a weaker ER-mitochondria interaction and a reduction of apoptosis. Furthermore, other recent studies have highlighted the key role of the ER-mitochondria juxtaposition in propagating apoptosis in the presence of pro-oxidant inducers of ER stress (25,62,137).

## **B. Autophagy**

MAMs are not only important for the coordination of mitochondrial integrity,  $\text{Ca}^{2+}$  handling and the apoptotic activity; they are also a primary element for the initiation and execution of the autophagic machinery. The mitochondria and ER are involved in autophagosome biogenesis. Initially, several ER proteins were found to localize to the autophagosome membrane. Then, electron and fluorescent microscopy analyses demonstrated that the ER and the initial isolation membrane of autophagosomes (the phagophore) are juxtaposed, and upon starvation-induced autophagy the cell forms the so-called omegasome, a phosphatidylinositol 3 –phosphate compartment connected to the ER that is fundamental for autophagosome formation. Alternatively, the autophagosome might be derived from mitochondria. It has been demonstrated that during starvation, the OMM “gifts” mitochondrial-derived membranes that will be used for autophagosome biogenesis. Furthermore, a crucial role of the ER-mitochondria connection in autophagy induction has been demonstrated. Indeed, MFN2 KO-derived cells are not able to undergo autophagy, supporting the possibility of a contribution of lipids from the ER to mitochondria (70). Additionally, these studies provided a further indication of the intimate relationship between MAMs and the autophagosome. However, the importance of ER-mitochondria contact sites for autophagosome formation remained controversial.

This question was answered in 2013 by an elegant study published in Nature, where it was demonstrated that autophagosome formation starts at MAMs. Immunofluorescence and electron microscopy, in addition to subcellular fractionation, showed that specific pre-autophagosome/ autophagosome markers (ATG14 and ATG5) localize to MAMs

under starved conditions. Consistently with these findings, upon starvation, DCFP1 (double FYVE domain-containing protein 1) translocates to the omegasome. In contrast, in PACS2 KO and MFN2 KO cells, both the accumulation of autophagic markers and the translocation of ER-related proteins are significantly reduced, indicating a stable role of MAMs during the completion of autophagosomes (72). In spite of these findings, the role of MAMs in the molecular mechanism of autophagy remains to be elucidated.

It is well known that the main regulator of autophagy is the serine/threonine kinase mTOR (mechanistic target of rapamycin) (95). This kinase exists in two protein complexes: mTOR complex-1 (mTORC1) and - 2 (mTORC2). Interestingly, it has been found that mTORC2 localizes to MAMs, where it activates AKT. Once activated, AKT appears to control MAMs integrity and mitochondrial physiology through PACS and hexokinase (HK2) phosphorylation. Furthermore, mTORC2-AKT regulates IP3R3 phosphorylation and  $Ca^{2+}$  release at MAMs (8). Despite this, the involvement of mTORC-2 in autophagy remains debatable. Nevertheless, it has been found that Rab32 (described above to be a MAMs protein essential for autophagosome formation) is critical for the regulation of mTORC2 activity (29). Overall, these findings may suggest an active role for this complex in autophagosome formation and the regulation of autophagic activity.

Other MAMs proteins also appear to regulate autophagy. One example is p66Shc, a protein that plays an important role in controlling the mammalian life span (146). It has recently been found that PKC $\beta$  and p66Shc overexpression leads to a reduction of autophagic activity and their roles in the modulation of autophagy appear to be interrelated. In support of this hypothesis, overexpression of PKC $\beta$  drives a strong increment of p66Shc phosphorylation and an augmentation of the transfer of p66Shc to

the mitochondrial compartment. Consistent with this finding, MEFs derived from PKC $\beta$  KO mice display a strong and significant reduction of both the phosphorylation and mitochondrial localization of p66Shc (141).

As has been well reviewed, different forms of specialized autophagy have been discovered in recent years (75). One of the most important is mitophagy, which is responsible for the selective removal of damaged and exhausted mitochondria. Several studies have demonstrated that two genes, PINK1 and parkin, are involved in the maintenance of a healthy population of mitochondria.

Parkin is a cytosolic E3 ubiquitin ligase that mediates the ubiquitylation of a number of target proteins. Parkin has been found to be cytoprotective under various conditions, and it has been reported to play a role in mitochondria under stress conditions (127). Parkin ubiquitinates several OMM proteins, including VDAC, MFN, DRP1, BCL2 and BAX (54,55). When severe damage impacts a population of mitochondria, the PINK1-parkin axis recognizes defective mitochondria, rapidly isolates them from the mitochondrial network and, finally, degrades them through the ubiquitin-proteasome and autophagic pathways (151). Recently, it has been demonstrated that mitochondria supply membrane material not only during serum starvation, but also during drug-induced autophagy, introducing a novel mechanism of parkin-associated mitophagy.

Cook et al. demonstrated that stress and starvation conditions and treatment with drugs capable of promoting autophagy increased both PINK1 and parkin localization to the mitochondrial compartment. Furthermore, using confocal and electron microscopy, these authors showed that mitochondria labeled with parkin are not only engulfed by the forming autophagosome but are also used to form new a autophagosome. Accordingly, inhibition of the mitophagic process through PINK1 knockdown restores normal

functional mitophagy in cells (30). In conclusion, this work could open new avenues for the discovery of novel roles of the ER-mitochondria contact sites in the regulation of the molecular pathways of general and selective autophagy (Fig. 5).

#### **IV. MAMs and Inflammation**

In addition to their established role as a signaling hub for  $\text{Ca}^{2+}$  and lipid transfer between the ER and mitochondria, MAMs have recently been shown to play a central role in the modulation of various key processes, including inflammasome signaling. A link between inflammation and the ER-mitochondria interface was established for the first time in 2011 in a study by Zhou and colleagues, who demonstrated a new role for mitochondria in NLRP3 inflammasome activation (190).

The NLRs are composed of 22 human genes that are characterized by the presence of a central nucleotide-binding oligomerization (NACHT) domain, C-terminal leucine-rich repeats (LRRs) and an N-terminal effector domain. Upon activation, select NLR family members form multiprotein complexes (termed inflammasomes) that serve as platforms for caspase-1 activation and the subsequent proteolytic maturation of the potent proinflammatory cytokine IL-1  $\beta$ . (171). Due to its association with numerous inflammatory diseases, the NLRP3 inflammasome is currently the most fully characterized, well-studied inflammasome. The key components of a functional NLRP3 inflammasome include NLRP3, the adaptor protein ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) and caspase-1 (159). Upon sensing a wide variety of danger signals, NLRP3 oligomerization and recruitment of ASC



and procaspase-1 trigger the autoactivation of caspase-1 and the maturation and secretion of proinflammatory cytokines, such as IL-1  $\beta$ .

Resting NLRP3 localizes to the cytosol and ER structures, whereas upon inflammasome activation using nigericin (an antibiotic) or monosodium urate, both NLRP3 and its adaptor ASC colocalize to the MAMs fraction. Thus, by virtue of its ER-mitochondria localization upon activation, the NLRP3 inflammasome is strategically located to receive signals emanating from mitochondria.

Previous studies have indicated that ROS represent a common integrator across several stimuli that activate the NLRP3 inflammasome. In addition to the ER and peroxisomes (19), mitochondria are the primary source of ROS. However, the source of NLRP3-activating ROS and the associated underlying mechanisms remain unclear.

Zhou and colleagues observed a correlation between mitochondrial ROS activity and the presence of IL-1  $\beta$  in the supernatant of the human THP1 macrophage cell line. To avoid cellular damage, ROS-generating mitochondria are constantly removed by mitophagy; these authors found that inhibition of the autophagic machinery affects IL-1  $\beta$  production, resulting in the accumulation of defective and ROS-producing mitochondria, which potentiates NLRP3-dependent inflammasome activation.

Although these results indicated that the prolonged presence of damaged, ROS-producing mitochondria is implicated in inflammasome activation, this evidence remained indirect. However, this finding suggests that MAMs may become locally enriched in ROS or ROS-derived signaling molecules and recruit ROS-sensing proteins. Consistent with this hypothesis, these authors inhibited the activity of the OMM channel VDAC and demonstrated that the knockdown of VDAC1/2 selectively abrogates NLRP3 inflammasome formation. In contrast, VDAC, and thus mitochondria, are not essential

for the activation of AIM2 or IPAF inflammasomes. VDAC activity is regulated by hexokinase and Bcl-2 family members; the overexpression of Bcl-2 leads to partial VDAC closure and a concomitant decrease of mitochondrial  $\text{Ca}^{2+}$  levels and ROS production. Stimulated macrophages isolated from Bcl-2-overexpressing transgenic mice exhibit decreased levels of IL-1  $\beta$  compared with cells from wild-type mice (Fig.6). Additional observations provide support for a pivotal role of mitochondria in NLRP3 inflammasome activation. ROS production can be specifically induced in mitochondria by inhibiting key enzymes of the electron transport chain. Addition of the complex I inhibitor rotenone results in a partial loss of  $\Psi_m$  and strong ROS production, as observed for the complex III inhibitor antimycin A; indeed, both drugs lead to NLRP3 inflammasome activation (111,190).

Furthermore, antioxidants specifically targeting mitochondria appear to block inflammasome activation and inflammation in general (20,124).

Bulua and colleagues identified mitochondrial ROS as a driver of inflammation in tumor necrosis factor receptor-associated periodic syndrome (TRAPS), which is an autoinflammatory disorder caused by missense mutations in the type-1 TNF receptor (TNFR1), and potentially in other autoinflammatory diseases (20). When mitochondrial respiration or ROS production is inhibited, inflammatory cytokine production in response to LPS is blunted. These results suggest a more general role for mitochondrial ROS in the induction of inflammatory cytokines upstream of inflammasome activation. In TRAPS, increased mitochondrial ROS result from enhanced oxidative phosphorylation; blockade of ROS production by the mitochondria provides a new therapeutic strategy for reducing the symptoms of TRAPS and other inflammatory states.

Taken together, these and other data suggest a model in which a wide range of danger signals converge to cause increased generation of mitochondrial ROS. A rise in mitochondrial oxidant production could therefore represent the common currency of all of these divergent stress signals, with subsequent activation of the NLRP3 inflammasome. For instance, although there is compelling evidence that mitochondrial oxidants regulate the inflammasome, the mechanisms through which inflammatory signals can regulate mitochondrial function and the precise mechanism by which the release of ROS can trigger NLRP3 activation have yet to be defined. The precise molecular target of mitochondrial ROS is poorly understood, and there is little insight regarding the specific role of oxidants in inflammatory circumstances.

Another NLRP3 binding partner, TXNIP, redistributes to MAMs/mitochondria in response to oxidative stress (157) or NLRP3 inflammasome activation (189). In resting cells, TXNIP interacts with TRX and is therefore unavailable for NLRP3 interaction.

Inflammasome activators, such as uric acid crystals, induce the dissociation of TXNIP from thioredoxin in a ROS-sensitive manner and allow it to bind NLRP3 and translocate to MAMs/mitochondria (189), raising the possibility that TXNIP is involved in IL-1  $\beta$  production through NLRP3 under ER stress conditions. TXNIP is a critical signaling node that links ER stress and inflammation. TXNIP is induced by ER stress through the PERK and IRE1 pathways, induces IL-1  $\beta$  mRNA transcription, activates IL-1  $\beta$  production by the NLRP3 inflammasome, and mediates ER stress-mediated  $\beta$ -cell death (134) (Fig.6).

MAMs play a central role not only in the communication between the ER and the mitochondria but also in maintaining various cellular processes such as the antiviral response.

Recently, a new role has been identified for the adaptor MAVS (mitochondrial antiviral signaling protein) as the mitochondrial anchor for NLRP3 inflammasome formation (167). MAVS is a well-known mitochondrial protein that plays a crucial role in RIG-like receptor (RLR) signaling pathways leading to type I IFN induction and NF- $\kappa$ B activation (160). Specifically, MAVS contains an N-terminal CARD-like domain and a C-terminal transmembrane domain that targets the protein to the mitochondrial membrane. The mitochondrial localization of MAVS represents the first example of a mitochondrial protein that plays a pivotal role in innate immunity. Viral RNAs are recognized in the cytosol by the helicases RIG-1 or MDA5 (melanoma differentiation-associated gene 5). The N-termini of RIG1 and MDA5 contain two CARD domains that interact with the CARD domain of the mitochondrial adaptor MAVS. After the recruitment of transactivators, MAVS induces phosphorylation of IRF3 and IRF7 and activation of NF- $\kappa$ B, leading to the production of type I IFNs and proinflammatory cytokines, respectively. It has recently been proposed that during RNA infection, RIG-1 is recruited to the MAMs to bind MAVS (77). Dynamic MAMs tethering to mitochondria and peroxisomes subsequently coordinates MAVS localization to form a signaling synapse between membranes. Importantly, the hepatitis C virus NS3/4A protease, which cleaves MAVS to support persistent infection, targets this synapse for MAVS proteolysis from the MAMs, but not from the mitochondria, to ablate RIG-1 signaling of immune responses. These results identify an innate immune signaling synapse in which the MAMs serves as the central scaffold that coordinates MAVS-dependent signaling of the RIG-1 pathway between mitochondria and peroxisomes (Fig.6). Collectively with the role of the MAMs in NLRP3 inflammasome signaling (190), these findings indicate that the MAMs plays a

central role in initiating both the innate immune and the inflammatory responses to infection.

Recently, Jacobs and colleagues demonstrated that gp78, which is an E3 ubiquitin ligase active in the ER-associated degradation (ERAD) pathway and localizes to the ER-mitochondria interface, is a novel regulator of RLR signaling (83). In addition to the enteroviruses coxsackie virus B and poliovirus, the depletion of gp78 results in a robust decrease of vesicular stomatitis virus infection and a corresponding enhancement of type I IFN signaling. Mechanistically, gp78 modulates type I IFN induction, altering both the expression and signaling of MAVS. These studies indicate an unexpected role for MAM-localized gp78 E3 ubiquitin ligase in the negative regulation of MAVS signaling. These results suggest two parallel pathways by which gp78 regulates MAVS expression and signaling; one pathway requires its E3 ubiquitin ligase and ERAD activity, whereas the second pathway requires the gp78 C-terminus and occurs via the association between this region and the N- and C-terminal domains of MAVS.

In addition to RIG-1, several other proteins that function in the area surrounding the mitochondria fine-tune the activities and functions of MAVS. Among these proteins, STING (STimulator of INterferon Genes) is particularly interesting, as it is enriched at MAMs; this protein interacts with RIG-1 and binds MAVS to activate a TBK-1- and IRF3-dependent cascade that ultimately induces the expression of type I IFN (82).

These results suggest that MAMs delineate a signaling synapse (involving both mitochondrial and ER components) that is essential for optimal antiviral responses.

Recently, it has been demonstrated that MAVS is required for optimal NLRP3 activity, mediating recruitment of NLRP3 to mitochondria, promoting the production of IL-1  $\beta$  and the pathophysiological activity of the NLRP3 inflammasome (167). The

recruitment, which depends on a short N-terminal sequence in NLRP3, promotes ASC “speckle” formation and the downstream biochemical events associated with the activity of the inflammasome. Contrary to these results, which support a role for MAVS in the activation of the NLRP3 inflammasome via nonviral stimuli such as LPS plus nigericin or LPS plus ATP, Park and colleagues demonstrated that MAVS regulates NLRP3 activation primarily in response to stimuli that directly engage MAVS, such as infection with Sendai virus (140). Activation of MAVS signaling by Sendai virus infection promotes NLRP3-dependent caspase-1 activation, whereas knockdown of MAVS expression clearly attenuated the activation of NLRP3 inflammasomes in THP-1 and mouse macrophages (Fig.6). These results suggest that MAVS facilitates the recruitment of NLRP3 to the mitochondria and may enhance its oligomerization and activation by bringing it in close proximity to mitochondrial ROS.

Given the important roles of the MAMs in different cellular processes, it is not surprising that numerous viral proteins target this structure. One well-characterized example is the human cytomegalovirus glycoprotein UL37 exon 1 (16) that traffics into the MAMs during permissive infection and induces alteration of the MAMs protein composition. This glycoprotein targets MAMs with two mitochondrial targeting signals (150) and is able to reduce ER  $Ca^{2+}$  contents, possibly by modulating the amount of  $Ca^{2+}$ -regulating chaperones and oxidoreductases such as BiP present on MAMs (188) or by increasing the targeting of GRP75 to the VDAC/IP3R/GRP75 ternary complex (16).

More recently, human immunodeficiency virus type 1 (HIV-1) viral protein R (Vpr) has been suggested to be present on the ER, MAMs and OMM, possibly via the integration of its C-terminal transmembrane domain (80). Vpr injures OMM and causes

loss of  $\Psi_m$  by post-transcriptionally reducing the expression of MFN2 and increasing mitochondrial deformation. Vpr also markedly decreases cytoplasmic levels of DRP1 and increases bulging in MAMs. Collectively, these results suggest that Vpr-mediated cellular damage may occur via an alternative protein transport pathway from the ER through the MAMs to the mitochondria, which is modulated by MFN2 and DRP1 (Fig.6). As we have outlined thus far, MAMs play a central role in the formation and regulation of the NLRP3 inflammasome. In addition to the two aforementioned nigericin and crystalline activators, several stimuli can trigger inducible activation of the NLRP3 complex, including extracellular ATP released by dying cells (117), cholesterol crystals (44), RNA and  $Ca^{2+}$  (85).

Murakami and colleagues elucidated a critical role for  $Ca^{2+}$  mobilization in the activation of the NLRP3 inflammasome by multiple stimuli (123). These authors demonstrated that blocking  $Ca^{2+}$  mobilization inhibits the assembly and activation of the NLRP3 inflammasome complex and that during ATP stimulation,  $Ca^{2+}$  signaling is pivotal in promoting mitochondrial damage. C/EBP homologous protein, which is a transcription factor that can modulate  $Ca^{2+}$  release from the ER, amplifies NLRP3 inflammasome activation, thus linking ER stress to the activation of the NLRP3 inflammasome.  $Ca^{2+}$  signaling is not sufficient for NLRP3 inflammasome activation, as indicated by the inability of the  $Ca^{2+}$  ionophore ionomycin to induce IL-1 $\beta$  production; however, only stimuli that mobilize  $Ca^{2+}$  in a manner leading to mitochondrial damage would activate the NLRP3 inflammasome.

Lee and colleagues recently confirmed and updated the role of  $Ca^{2+}$  in inflammation; these authors found that the murine  $Ca^{2+}$ -sensing receptor (CaSR)

strongly activates the NLRP3 inflammasome, which is mediated by increased intracellular  $\text{Ca}^{2+}$  and decreased cellular cyclic AMP (105). CaSR activates the NLRP3 inflammasome through phospholipase C, which catalyzes inositol-1,4,5-trisphosphate production and thereby induces release of  $\text{Ca}^{2+}$  from ER stores; the increased cytoplasmic  $\text{Ca}^{2+}$  promotes the assembly of inflammasome components. Moreover, G-protein-coupled receptors can activate the inflammasome, indicating that increased extracellular  $\text{Ca}^{2+}$  functions as a specific amplifier of inflammation (155). Activation is mediated by signaling through the  $\text{Ca}^{2+}$ -signaling receptor and GPRC6A via the phosphatidyl inositol/ $\text{Ca}^{2+}$  pathway.

Recently, Nakahira and colleagues demonstrated that treatment with LPS and ATP release mtDNA into the cytosolic compartment and that this requires activation of the NLRP3 inflammasome, directly contributing to downstream activation of caspase-1 (124) (Fig.6).

Recently, Oelze and colleagues demonstrated that glutathione peroxidase-1 (GPx-1) ablation in aging animals has a substantial impact on the burden of oxidative stress and injury (130). They observed that the age-dependent increase in the infiltration of cardiovascular tissue with leukocytes is more pronounced in GPx-1-deficient mice, suggesting that GPx-1 deficiency may lead to an inflammatory phenotype of the vasculature, which is a condition that has been reported to contribute to increased oxidative stress and vascular/endothelial dysfunction (178).

These findings give rise to further speculations. For example, MAMs may be a key player in aging-related, low-grade inflammation, as aging is associated with increased mitochondrial ROS formation, and MAMs contain several redox-sensitive components of the NLRP3 inflammasome.



Collectively, these findings highlight the central role of MAMs in the coordination of inflammasome formation and antiviral immunity. Future studies are necessary to fully explore the biological significance of MAMs during these processes.

## **V. MAMs Deregulation in the Pathogenesis of Neurological Disorders**

Alterations in mitochondrial and ER homeostasis and the link between MAMs homeostasis and cellular derangement are common features of several neuronal diseases in which genetic models and environmental factors permitted the identification of common traits in the pathogenic routes. Indeed, with the increasing amount of information on MAMs, considerable evidence indicates that MAMs play an important role in neuronal disease. Analysis of the proteins present at MAMs through a mass spectrometry-based proteomic characterization from mouse brain tissue in association with a quantitative validation method to distinguish true MAMs proteins from contaminating proteins, Poston and colleagues (147) identified several proteins related to different neuronal-based diseases, such as movement disorders (chorea and Parkinson's disease), genetic disorders (Huntington's disease), and neurodegenerative diseases (schizophrenia, dementia, and seizures). This evidence suggests that several neuronal disorders share an alteration of MAMs homeostasis, where two crucial organelles (the mitochondrion and the ER) for neuronal cells are in close contact with a sustained crosstalk. We can therefore speculate that neuronal diseases are MAMs-related disorders.

Here, we briefly discuss alterations in MAMs functions that appear to be important in the pathogenesis of selected human neuronal pathologies. We will summarize only

the possible link between MAMs and these pathologies, referring readers to the literature for details of the individual pathologies.

$\text{Ca}^{2+}$  homeostasis represents a link between MAMs and neuronal diseases, particularly through the alterations in  $\text{Ca}^{2+}$  crosstalk between the ER and mitochondria at MAMs, which are a hotspot of  $\text{Ca}^{2+}$  signaling domains (142).

Various experimental observations have suggested that an alteration of intracellular  $\text{Ca}^{2+}$  homeostasis contributes to the development of FAD and, more generally, to the pathogenesis of AD. Indeed, mutations in PS have been shown to alter ER  $\text{Ca}^{2+}$  release, affecting the mitochondria in a number of cell models (69,106,108). Interestingly, PSs are highly enriched in MAMs (158).

Different, and, in some cases, contrasting, hypotheses have been proposed. Some authors argue that ER  $\text{Ca}^{2+}$  overload is because wild-type PSs, but not the FAD mutants, can form  $\text{Ca}^{2+}$ -permeable leak channels in the ER (173), thus providing a clear case for enhanced  $\text{Ca}^{2+}$  release in their pathological model. Subsequent studies from other groups have presented results that are not entirely consistent with this hypothesis (26,49,57,92,187). This experimental discrepancy has been explained in part by the observation that PS1 and PS2 play distinct roles: PS2, but not PS1, modulates the ER-mitochondria tethering by increasing the number and/or the extent of their contact sites and, in turn, the  $\text{Ca}^{2+}$  crosstalk between the ER and mitochondria. FAD-linked PS2 mutations lead to a larger increase in ER-mitochondria interactions and, consequently, to an altered (and deleterious)  $\text{Ca}^{2+}$  transfer from the ER to mitochondria (Fig.7).

There is currently a consensus that an increased association between MAMs and mitochondria is linked to the pathogenesis of AD; indeed, in different models of AD, the area of close apposition between mitochondria and the ER (i.e., the MAMs) and the

processes that occur at MAMs are enhanced compared with wild-type cells (158). Consistent with these observations,  $\gamma$ -secretase and PS activity is lower in MFN2-deficient cells that contain very few MAMs than in wild-type cells (5). Interestingly, this occurs not only in FAD but also in sporadic AD. However, these results were obtained in only fibroblasts from patients, not in neurons.

Several studies support the theory that the neuronal demise is potentiated by vascular alterations in the early stages of the disease. Recently, it has been demonstrated that amyloid- $\beta$  (A  $\beta$ ) induces ER stress in brain endothelial cells and triggers a mitochondria-mediated apoptotic cell death pathway involving ER-to-mitochondria  $\text{Ca}^{2+}$  transfer, decrease of  $\Psi_m$ , and release of proapoptotic factors (50), thus suggesting the participation of MAMs in this pathogenetic route (Fig.7).

Regardless of how the synergistic “ $\text{Ca}^{2+}$  hit” occurs, mitochondrial dysfunction appears to be an obligatory downstream step in the pathogenesis of AD. Electron microscopy analysis of mitochondria in various regions of AD-affected brains revealed significant morphological organelle alterations (6).

A  $\beta$  peptides increased neuronal ROS production, activated the mitochondrial fission proteins DRP1 and FIS1 and caused mitochondrial fragmentation (7).

Moreover, A  $\beta$  peptides modulate the mPTP (Fig.7). A  $\beta$  peptides have been shown to inhibit mitochondrial respiration (34) and facilitate the opening of the mPTP. However, knockout mouse models for cyclophilin D, which is an essential component of mPTP activity, exhibit improved cognitive abilities and a minor A  $\beta$  -mediated reduction of long-term potentiation (43).

MAMs also play a key role in Parkinson’s disease (PD) (Fig.7). This hypothesis is

supported by the identification of a cohort of proteins involved in the familial forms of PD that appear to share intracellular localization of MAMs and possibly indicate a signaling role for  $\text{Ca}^{2+}$ . Specifically, mutations were reported in genes encoding for  $\alpha$ -synuclein, DJ-1, PINK1, and parkin.

$\alpha$ -Synuclein is localized to mitochondria-associated ER membranes (68). The different levels of  $\alpha$ -synuclein oligomerization have been linked to cell death. In particular, a heterogeneous mixture of small oligomers of  $\alpha$ -synuclein can lead to  $\text{Ca}^{2+}$  dysregulation to the point of mPTP activation and commitment to neuronal cell death (36). Studies have shown that  $\alpha$ -synuclein positively affects  $\text{Ca}^{2+}$  transfer from the ER to the mitochondria (22,89,119,161). This effect is correlated with an increase in the number of MAMs through the C-terminal of the  $\alpha$ -synuclein domain (22). Moreover, it has been proposed that the accumulation of  $\alpha$ -synuclein in the cells causes the redistribution of  $\alpha$ -synuclein to localized foci and reduces the ability of mitochondria to accumulate  $\text{Ca}^{2+}$ , resulting in augmented autophagy with the risk of altering normal mitochondrial homeostasis (22).

DJ-1 is largely cytoplasmic, except for a pool localized in mitochondria, most likely within the mitochondrial intermembrane space and in the matrix, whereas little if any DJ-1 is associated with the outer and inner mitochondrial membranes (41). Numerous studies support the role of DJ-1 in mitigating oxidative stress and in the maintenance of mitochondrial homeostasis (41). A recent study proposed that DJ-1 modulates ER-mitochondrial  $\text{Ca}^{2+}$  crosstalk, favoring the tethering between the two organelles and, thus, MAMs formation (135).

Parkin is a ubiquitin-protein ligase that localizes to the mitochondrial matrix, where it enhances mitochondrial gene transcription and biogenesis in proliferating cells

(84). Parkin has been proposed to play a neuroprotective role, promoting the clearance of damaged mitochondria through the mitophagic process (127). In *Drosophila*, parkin null mutants exhibit defects in mitochondrial function and increased oxidative stress. In contrast, overexpression of parkin in cultured cells prevents mitochondrial swelling and stress-induced apoptosis (84). Parkin overexpression stimulates MAMs formation and, in turn, physically and functionally enhances ER–mitochondria coupling, thus favoring  $\text{Ca}^{2+}$  transfer from the ER to the mitochondria and energy metabolism (23).

As previously described, parkin associates with PINK1 in mitochondrial quality control pathways, promoting the selective degradation of damaged mitochondria through mitophagy (175,185).

PINK1 is unambiguously localized to mitochondrial membranes, and PINK1 overexpression protects cells from mitochondrial depolarization and apoptosis (183). Loss-of-function mutations are responsible for dopaminergic neuronal degeneration in *Drosophila* (139). Overexpression of parkin has been shown to rescue the mitochondrial dysfunction caused by PINK1 deficiency (184).

Finally, a mutant form of PINK1 has been shown to exacerbate mitochondrial alterations (disturbing mitochondrial  $\text{Ca}^{2+}$  fluxes) promoted by an  $\alpha$ -synuclein mutant, thus suggesting cooperative roles for these two proteins (118) .

GM1-gangliosidosis represents an additional example of a MAMs-related pathology. This neurodegenerative disease is characterized by GM1-ganglioside (GM1) accumulation within MAMs in brain tissue (156).

Additionally, series of independent observations highlighted a possible role for MAMs in Huntington's disease. Mutant, but not wild-type huntingtin (Htt; the protein that, when mutated, is responsible for the disease), localizes to the mitochondrial membranes

in neurons (136). Htt forms a ternary complex with Htt-associated protein-1A (HAP-1A) and IP3R (a protein enriched at MAMs). In this complex, mutant Htt, but not wild-type Htt, facilitates  $\text{Ca}^{2+}$  release from the ER and renders neurons more sensitive to  $\text{Ca}^{2+}$ -mediated cellular dysfunction via mitochondrial  $\text{Ca}^{2+}$  overload (9) and mPTP opening (Fig.8) (27).

MAMs involvement appears to also be important in amyotrophic lateral sclerosis (ALS). Vesicle-associated membrane protein-associated protein B (VAPB) has been proposed to play a role in the pathogenesis of this neurological disease, and recent studies localize this protein at MAMs, where it interacts with protein tyrosine phosphatase interacting protein 51 (PTPIP51), which is an outer mitochondrial membrane protein, and regulates ER-mitochondrial  $\text{Ca}^{2+}$  crosstalk. The VAPBP mutant associated with ALS has been demonstrated to alter its binding to PTPIP51 and exacerbate ER-mitochondrial  $\text{Ca}^{2+}$  transfer (39) (Fig.8).

Sig1R, which is another important protein that is particularly enriched at MAMs and is involved in  $\text{Ca}^{2+}$  homeostasis, has been proposed to be involved in the pathogenesis of ALS (148) (Fig.8).

Interestingly, in several studies, mitochondrial dysfunction has been reported to be frequently associated with demyelination, whereas proper mitochondrial function is required for correct oligodendrocyte differentiation and myelination. Bonora and colleagues reported that correct mitochondrial  $\text{Ca}^{2+}$  signaling and, thus, MAMs activity are impaired in conditions mimicking the proinflammatory environment to which the oligodendrocytes are exposed in multiple sclerosis patients. These abnormalities result in inefficient oligodendrocyte differentiation (13).

Finally, MAMs are also emerging as critical intracellular domains in the pathogenesis of the incurable disease Wolfram syndrome. This concept is demonstrated by the observation that Miner1, which is a protein that if mutated causes Wolfram syndrome, is enriched at MAMs and is involved in ER stress and  $Ca^{2+}$  signaling around MAMs, as previously described for other proteins involved in mitochondrial structure and physiology (180).

These results highlight MAMs involvement in the pathogenesis of several neurological disorders. Studies on this topic are ongoing in several groups, including ours, and we predict that in the future, new findings will consolidate this concept for the disorders presented here and for numerous others.

## **VI. Concluding Remarks**

Overall, the picture emerging from the study of MAMs appears to be extremely complex (Fig.9), with several uncertainties to resolve. Nevertheless, the common role of MAMs in important physiopathological pathways is clear, providing a leading theme for future studies. However, whether alterations in MAMs represent a response to the disease pathogenesis or directly contribute to the disease has not yet been unequivocally established. In any case, MAMs represent a promising pharmacological target for several important human diseases. Finally, the following important questions remain open: i) What are the entire proteomes of the MAMs in the different cell and tissue types under normal conditions and under stress or pathological conditions? ii) Are the MAMs identical within the cell, or is any cell endowed with several different types of MAMs with

respect to protein composition? iii) What are the precise molecular mechanisms of MAMs formation? and iv) How are the proteins and lipids targeted to MAMs?

**Acknowledgments.** *This study was supported by the Italian Association for Cancer Research (AIRC) and local funding from the University of Ferrara to Paolo Pinton and Carlotta Giorgi; and from Telethon (GGP11139B), the Italian Cystic Fibrosis Foundation (Grant 19/2014), the Italian Ministry of Health, the Italian Ministry of Education, University and Research (COFIN, FIRB, and Futuro in Ricerca) to Paolo Pinton. Mariusz R. Wieckowski and Jerzy Duszyński were supported by the Polish National Science Center (UMO-2011/11/M/NZ3/02128), Polish Ministry of Science and Higher Education grant W100/HFSC/2011 and Grant HFSP RGP0027/2011. Simone Patergnani was supported by a research fellowship from FISM (Fondazione Italiana Sclerosi Multipla), cod. 2012/B/11.*



## REFERENCES:

1. Alberts B. The cell as a collection of protein machines: preparing the next generation of molecular biologists. *Cell* 92: 291-4, 1998.
2. Anelli T, Bergamelli L, Margittai E, Rimessi A, Fagioli C, Malgaroli A, Pinton P, Ripamonti M, Rizzuto R, Sitia R. Ero1alpha regulates Ca(2+) fluxes at the endoplasmic reticulum-mitochondria interface (MAM). *Antioxid Redox Signal* 16: 1077-87, 2012.
3. Appenzeller-Herzog C, Riemer J, Zito E, Chin KT, Ron D, Spiess M, Ellgaard L. Disulphide production by Ero1alpha-PDI relay is rapid and effectively regulated. *EMBO J* 29: 3318-29, 2010.
4. Area-Gomez E, de Groof AJ, Boldogh I, Bird TD, Gibson GE, Koehler CM, Yu WH, Duff KE, Yaffe MP, Pon LA, Schon EA. Presenilins are enriched in endoplasmic reticulum membranes associated with mitochondria. *Am J Pathol* 175: 1810-6, 2009.
5. Area-Gomez E, Del Carmen Lara Castillo M, Tambini MD, Guardia-Laguarta C, de Groof AJ, Madra M, Ikenouchi J, Umeda M, Bird TD, Sturley SL, Schon EA. Upregulated function of mitochondria-associated ER membranes in Alzheimer disease. *EMBO J* 31: 4106-23, 2012.
6. Baloyannis SJ. Mitochondria are related to synaptic pathology in Alzheimer's disease. *Int J Alzheimers Dis* 2011: 305395, 2011.
7. Barsoum MJ, Yuan H, Gerencser AA, Liot G, Kushnareva Y, Graber S, Kovacs I, Lee WD, Waggoner J, Cui J, White AD, Bossy B, Martinou JC, Youle RJ, Lipton SA, Ellisman MH, Perkins GA, Bossy-Wetzel E. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. *EMBO J* 25: 3900-11, 2006.
8. Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demarex N, Hall MN. Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology. *Proc Natl Acad Sci USA* 110: 12526-34, 2013.
9. Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. *Biochem Biophys Res Commun* 322: 1310-7, 2004.
10. Bononi A, Agnoletto C, De Marchi E, Marchi S, Patergnani S, Bonora M, Giorgi C, Missiroli S, Poletti F, Rimessi A, Pinton P. Protein kinases and phosphatases in the control of cell fate. *Enzyme Res* 2011: 329098, 2011.
11. Bononi A, Bonora M, Marchi S, Missiroli S, Poletti F, Giorgi C, Pandolfi PP, Pinton P. Identification of PTEN at the ER and MAMs and its regulation of Ca(2+) signaling and apoptosis in a protein phosphatase-dependent manner. *Cell Death Differ* 20: 1631-43, 2013.
12. Bonora M, Bononi A, De Marchi E, Giorgi C, Lebedzinska M, Marchi S, Patergnani S, Rimessi A, Suski JM, Wojtala A, Wieckowski MR, Kroemer G, Galluzzi L, Pinton P. Role of the c subunit of the FO ATP synthase in mitochondrial permeability transition. *Cell Cycle* 12: 674-83, 2013.
13. Bonora M, De Marchi E, Patergnani S, Suski JM, Celsi F, Bononi A, Giorgi C, Marchi S, Rimessi A, Duszynski J, Pozzan T, Wieckowski MR, Pinton P. Tumor necrosis factor-alpha impairs oligodendroglial differentiation through a mitochondria-dependent process. *Cell Death Differ* 21: 1198-208, 2014.

14. Bonora M, Patergnani S, Rimessi A, De Marchi E, Suski JM, Bononi A, Giorgi C, Marchi S, Missiroli S, Poletti F, Wieckowski MR, Pinton P. ATP synthesis and storage. *Purinergic Signal* 8: 343-57, 2012.
15. Bonora M, Wieckowski MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L, Pinton P. Molecular mechanisms of cell death: central implication of ATP synthase in mitochondrial permeability transition. *Oncogene* 0, 2014.
16. Bozidis P, Williamson CD, Wong DS, Colberg-Poley AM. Trafficking of UL37 proteins into mitochondrion-associated membranes during permissive human cytomegalovirus infection. *J Virol* 84: 7898-903, 2010.
17. Bravo R, Vicencio JM, Parra V, Troncoso R, Munoz JP, Bui M, Quiroga C, Rodriguez AE, Verdejo HE, Ferreira J, Iglewski M, Chiong M, Simmen T, Zorzano A, Hill JA, Rothermel BA, Szabadkai G, Lavandro S. Increased ER-mitochondrial coupling promotes mitochondrial respiration and bioenergetics during early phases of ER stress. *J Cell Sci* 124: 2143-52, 2011.
18. Brooks C, Wei Q, Feng L, Dong G, Tao Y, Mei L, Xie ZJ, Dong Z. Bak regulates mitochondrial morphology and pathology during apoptosis by interacting with mitofusins. *Proc Natl Acad Sci U S A* 104: 11649-54, 2007.
19. Brown GC, Borutaite V. There is no evidence that mitochondria are the main source of reactive oxygen species in mammalian cells. *Mitochondrion* 12: 1-4, 2012.
20. Bulua AC, Simon A, Maddipati R, Pelletier M, Park H, Kim KY, Sack MN, Kastner DL, Siegel RM. Mitochondrial reactive oxygen species promote production of proinflammatory cytokines and are elevated in TNFR1-associated periodic syndrome (TRAPS). *J Exp Med* 208: 519-33, 2011.
21. Cabibbo A, Pagani M, Fabbri M, Rocchi M, Farmery MR, Bulleid NJ, Sitia R. ERO1-L, a human protein that favors disulfide bond formation in the endoplasmic reticulum. *J Biol Chem* 275: 4827-33, 2000.
22. Cali T, Ottolini D, Negro A, Brini M. alpha-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. *J Biol Chem* 287: 17914-29, 2012.
23. Cali T, Ottolini D, Negro A, Brini M. Enhanced parkin levels favor ER-mitochondria crosstalk and guarantee Ca(2+) transfer to sustain cell bioenergetics. *Biochim Biophys Acta* 1832: 495-508, 2013.
24. Camici GG, Schiavoni M, Francia P, Bachschmid M, Martin-Padura I, Hersberger M, Tanner FC, Pelicci P, Volpe M, Anversa P, Luscher TF, Cosentino F. Genetic deletion of p66(Shc) adaptor protein prevents hyperglycemia-induced endothelial dysfunction and oxidative stress. *Proc Natl Acad Sci U S A* 104: 5217-22, 2007.
25. Chami M, Oules B, Szabadkai G, Tacine R, Rizzuto R, Paterlini-Brechot P. Role of SERCA1 truncated isoform in the proapoptotic calcium transfer from ER to mitochondria during ER stress. *Mol Cell* 32: 641-51, 2008.
26. Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK. Mechanism of Ca<sup>2+</sup> disruption in Alzheimer's disease by presenilin regulation of InsP<sub>3</sub> receptor channel gating. *Neuron* 58: 871-83, 2008.
27. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. *Hum Mol Genet* 13: 1407-20, 2004.

28. Cipolat S, Martins de Brito O, Dal Zilio B, Scorrano L. OPA1 requires mitofusin 1 to promote mitochondrial fusion. *Proc Natl Acad Sci U S A* 101: 15927-32, 2004.
29. Colombi M, Molle KD, Benjamin D, Rattenbacher-Kiser K, Schaefer C, Betz C, Thiemeyer A, Regenass U, Hall MN, Moroni C. Genome-wide shRNA screen reveals increased mitochondrial dependence upon mTORC2 addiction. *Oncogene* 30: 1551-65, 2011.
30. Cook KL, Soto-Pantoja DR, Abu-Asab M, Clarke PA, Roberts DD, Clarke R. Mitochondria directly donate their membrane to form autophagosomes during a novel mechanism of parkin-associated mitophagy. *Cell Biosci* 4: 16, 2014.
31. Copeland DE, Dalton AJ. An association between mitochondria and the endoplasmic reticulum in cells of the pseudobranch gland of a teleost. *J Biophys Biochem Cytol* 5: 393-6, 1959.
32. Cosentino F, Francia P, Camici GG, Pelicci PG, Luscher TF, Volpe M. Final common molecular pathways of aging and cardiovascular disease: role of the p66Shc protein. *Arterioscler Thromb Vasc Biol* 28: 622-8, 2008.
33. Cosentino K, Garcia-Saez AJ. Mitochondrial alterations in apoptosis. *Chem Phys Lipids* 181: 62-75, 2014.
34. Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barnham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Masters CL, Trounce IA. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. *J Neurosci* 25: 672-9, 2005.
35. Dallaporta B, Marchetti P, de Pablo MA, Maise C, Duc HT, Metivier D, Zamzami N, Geuskens M, Kroemer G. Plasma membrane potential in thymocyte apoptosis. *J Immunol* 162: 6534-42, 1999.
36. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretschmar H, Hengerer B, Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. *J Neurosci* 27: 9220-32, 2007.
37. De Marchi E, Baldassari F, Bononi A, Wieckowski MR, Pinton P. Oxidative stress in cardiovascular diseases and obesity: role of p66Shc and protein kinase C. *Oxid Med Cell Longev* 2013: 564961, 2013.
38. De Stefani D, Bononi A, Romagnoli A, Messina A, De Pinto V, Pinton P, Rizzuto R. VDAC1 selectively transfers apoptotic Ca<sup>2+</sup> signals to mitochondria. *Cell Death Differ* 19: 267-73, 2012.
39. De Vos KJ, Morotz GM, Stoica R, Tudor EL, Lau KF, Ackerley S, Warley A, Shaw CE, Miller CC. VAPB interacts with the mitochondrial protein PTPIP51 to regulate calcium homeostasis. *Hum Mol Genet* 21: 1299-311, 2012.
40. Decuypere JP, Monaco G, Bultynck G, Missiaen L, De Smedt H, Parys JB. The IP(3) receptor-mitochondria connection in apoptosis and autophagy. *Biochim Biophys Acta* 1813: 1003-13, 2011.
41. Dodson MW, Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. *Curr Opin Neurobiol* 17: 331-7, 2007.
42. Drose S, Brandt U, Wittig I. Mitochondrial respiratory chain complexes as sources and targets of thiol-based redox-regulation. *Biochim Biophys Acta* 1844: 1344-54, 2014.
43. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D

- deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. *Nat Med* 14: 1097-105, 2008.
44. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. *Nature* 464: 1357-61, 2010.
  45. Ellgaard L, Ruddock LW. The human protein disulphide isomerase family: substrate interactions and functional properties. *EMBO Rep* 6: 28-32, 2005.
  46. Ellis RJ. Macromolecular crowding: obvious but underappreciated. *Trends Biochem Sci* 26: 597-604, 2001.
  47. Enyedi B, Varnai P, Geiszt M. Redox state of the endoplasmic reticulum is controlled by Ero1L-alpha and intraluminal calcium. *Antioxid Redox Signal* 13: 721-9, 2010.
  48. Eskes R, Antonsson B, Osen-Sand A, Montessuit S, Richter C, Sadoul R, Mazzei G, Nichols A, Martinou JC. Bax-induced cytochrome C release from mitochondria is independent of the permeability transition pore but highly dependent on Mg<sup>2+</sup> ions. *J Cell Biol* 143: 217-24, 1998.
  49. Fedrizzi L, Lim D, Carafoli E, Brini M. Interplay of the Ca<sup>2+</sup>-binding protein DREAM with presenilin in neuronal Ca<sup>2+</sup> signaling. *J Biol Chem* 283: 27494-503, 2008.
  50. Fonseca AC, Moreira PI, Oliveira CR, Cardoso SM, Pinton P, Pereira CF. Amyloid-Beta Disrupts Calcium and Redox Homeostasis in Brain Endothelial Cells. *Mol Neurobiol*, 2014.
  51. Frank S, Gaume B, Bergmann-Leitner ES, Leitner WW, Robert EG, Catez F, Smith CL, Youle RJ. The role of dynamin-related protein 1, a mediator of mitochondrial fission, in apoptosis. *Dev. Cell* 1: 515-525, 2001.
  52. Fujimoto M, Hayashi T, Su TP. The role of cholesterol in the association of endoplasmic reticulum membranes with mitochondria. *Biochem Biophys Res Commun* 417: 635-9, 2012.
  53. Garcia Fernandez M, Troiano L, Moretti L, Nasi M, Pinti M, Salvioli S, Dobrucki J, Cossarizza A. Early changes in intramitochondrial cardiolipin distribution during apoptosis. *Cell Growth Differ* 13: 449-55, 2002.
  54. Gegg ME, Cooper JM, Chau KY, Rojo M, Schapira AH, Taanman JW. Mitofusin 1 and mitofusin 2 are ubiquitinated in a PINK1/parkin-dependent manner upon induction of mitophagy. *Hum Mol Genet* 19: 4861-70, 2010.
  55. Geisler S, Holmstrom KM, Skujat D, Fiesel FC, Rothfuss OC, Kahle PJ, Springer W. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. *Nat Cell Biol* 12: 119-31, 2010.
  56. Gertz M, Fischer F, Wolters D, Steegborn C. Activation of the lifespan regulator p66Shc through reversible disulfide bond formation. *Proc Natl Acad Sci U S A* 105: 5705-9, 2008.
  57. Giacomello M, Barbiero L, Zatti G, Squitti R, Binetti G, Pozzan T, Fasolato C, Ghidoni R, Pizzo P. Reduction of Ca<sup>2+</sup> stores and capacitative Ca<sup>2+</sup> entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. *Neurobiol Dis* 18: 638-48, 2005.
  58. Gilady SY, Bui M, Lynes EM, Benson MD, Watts R, Vance JE, Simmen T. Ero1alpha requires oxidizing and normoxic conditions to localize to the mitochondria-associated membrane (MAM). *Cell Stress Chaperones* 15: 619-29, 2010.

59. Giorgi C, Agnoletto C, Baldini C, Bononi A, Bonora M, Marchi S, Missiroli S, Patergnani S, Poletti F, Rimessi A, Zavan B, Pinton P. Redox control of protein kinase C: cell- and disease-specific aspects. *Antioxid Redox Signal* 13: 1051-85, 2010.
60. Giorgi C, Baldassari F, Bononi A, Bonora M, De Marchi E, Marchi S, Missiroli S, Patergnani S, Rimessi A, Suski JM, Wieckowski MR, Pinton P. Mitochondrial Ca(2+) and apoptosis. *Cell Calcium* 52: 36-43, 2012.
61. Giorgi C, De Stefani D, Bononi A, Rizzuto R, Pinton P. Structural and functional link between the mitochondrial network and the endoplasmic reticulum. *Int J Biochem Cell Biol* 41: 1817-27, 2009.
62. Giorgi C, Ito K, Lin HK, Santangelo C, Wieckowski MR, Lebedzinska M, Bononi A, Bonora M, Duszynski J, Bernardi R, Rizzuto R, Tacchetti C, Pinton P, Pandolfi PP. PML regulates apoptosis at endoplasmic reticulum by modulating calcium release. *Science* 330: 1247-51, 2010.
63. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, Pelicci PG. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. *Cell* 122: 221-233, 2005.
64. Giorgio M, Migliaccio E, Orsini F, Paolucci D, Moroni M, Contursi C, Pelliccia G, Luzi L, Minucci S, Marcaccio M, Pinton P, Rizzuto R, Bernardi P, Paolucci F, Pelicci PG. Electron transfer between cytochrome c and p66Shc generates reactive oxygen species that trigger mitochondrial apoptosis. *Cell* 122: 221-33, 2005.
65. Graiani G, Lagrasta C, Migliaccio E, Spillmann F, Meloni M, Madeddu P, Quaini F, Padura IM, Lanfrancone L, Pelicci P, Emanuelli C. Genetic deletion of the p66Shc adaptor protein protects from angiotensin II-induced myocardial damage. *Hypertension* 46: 433-40, 2005.
66. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. *Science* 305: 626-629, 2004.
67. Grisham MB. Methods to detect hydrogen peroxide in living cells: Possibilities and pitfalls. *Comp Biochem Physiol A Mol Integr Physiol* 165: 429-38, 2013.
68. Guardia-Laguarta C, Area-Gomez E, Rub C, Liu Y, Magrane J, Becker D, Voos W, Schon EA, Przedborski S. alpha-Synuclein is localized to mitochondria-associated ER membranes. *J Neurosci* 34: 249-59, 2014.
69. Guo Q, Furukawa K, Sopher BL, Pham DG, Xie J, Robinson N, Martin GM, Mattson MP. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. *Neuroreport* 8: 379-83, 1996.
70. Hailey DW, Rambold AS, Satpute-Krishnan P, Mitra K, Sougrat R, Kim PK, Lippincott-Schwartz J. Mitochondria supply membranes for autophagosome biogenesis during starvation. *Cell* 141: 656-67, 2010.
71. Halliwell B, Whiteman M. Measuring reactive species and oxidative damage in vivo and in cell culture: how should you do it and what do the results mean? *Br J Pharmacol* 142: 231-55, 2004.
72. Hamasaki M, Furuta N, Matsuda A, Nezu A, Yamamoto A, Fujita N, Oomori H, Noda T, Haraguchi T, Hiraoka Y, Amano A, Yoshimori T. Autophagosomes form at ER-mitochondria contact sites. *Nature* 495: 389-93, 2013.
73. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. *Cell Death Differ* 7: 1182-91, 2000.

74. Hatahet F, Ruddock LW. Protein disulfide isomerase: a critical evaluation of its function in disulfide bond formation. *Antioxid Redox Signal* 11: 2807-50, 2009.
75. Hattori N, Saiki S, Imai Y. Regulation by mitophagy. *Int J Biochem Cell Biol* 53: 147-50, 2014.
76. Higo T, Hattori M, Nakamura T, Natsume T, Michikawa T, Mikoshiba K. Subtype-specific and ER lumenal environment-dependent regulation of inositol 1,4,5-trisphosphate receptor type 1 by ERp44. *Cell* 120: 85-98, 2005.
77. Horner SM, Liu HM, Park HS, Briley J, Gale M, Jr. Mitochondrial-associated endoplasmic reticulum membranes (MAM) form innate immune synapses and are targeted by hepatitis C virus. *Proc Natl Acad Sci U S A* 108: 14590-5, 2011.
78. Horvath SE, Daum G. Lipids of mitochondria. *Prog Lipid Res* 52: 590-614, 2013.
79. Hu Y, Wang X, Zeng L, Cai DY, Sabapathy K, Goff SP, Firpo EJ, Li B. ERK phosphorylates p66shcA on Ser36 and subsequently regulates p27kip1 expression via the Akt-FOXO3a pathway: implication of p27kip1 in cell response to oxidative stress. *Mol Biol Cell* 16: 3705-18, 2005.
80. Huang CY, Chiang SF, Lin TY, Chiou SH, Chow KC. HIV-1 Vpr triggers mitochondrial destruction by impairing Mfn2-mediated ER-mitochondria interaction. *PLoS One* 7: e33657, 2012.
81. Ishihara N, Nomura M, Jofuku A, Kato H, Suzuki SO, Masuda K, Otera H, Nakanishi Y, Nonaka I, Goto Y, Taguchi N, Morinaga H, Maeda M, Takayanagi R, Yokota S, Mihara K. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. *Nat Cell Biol* 11: 958-66, 2009.
82. Ishikawa H, Barber GN. STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. *Nature* 455: 674-8, 2008.
83. Jacobs JL, Zhu J, Sarkar SN, Coyne CB. Regulation of mitochondrial antiviral signaling (MAVS) expression and signaling by the mitochondria-associated endoplasmic reticulum membrane (MAM) protein Gp78. *J Biol Chem* 289: 1604-16, 2014.
84. Jiang H, Ren Y, Zhao J, Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. *Hum Mol Genet* 13: 1745-54, 2004.
85. Jin C, Frayssinet P, Pelker R, Cwirka D, Hu B, Vignery A, Eisenbarth SC, Flavell RA. NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy. *Proc Natl Acad Sci U S A* 108: 14867-72, 2011.
86. Kagan VE, Tyurin VA, Jiang J, Tyurina YY, Ritov VB, Amoscato AA, Osipov AN, Belikova NA, Kapralov AA, Kini V, Vlasova, II, Zhao Q, Zou M, Di P, Svistunenko DA, Kurnikov IV, Borisenko GG. Cytochrome c acts as a cardiolipin oxygenase required for release of proapoptotic factors. *Nat Chem Biol* 1: 223-32, 2005.
87. Kalwarczyk T, Ziebac N, Bielejewska A, Zaboklicka E, Koynov K, Szymanski J, Wilk A, Patkowski A, Gapinski J, Butt HJ, Holyst R. Comparative analysis of viscosity of complex liquids and cytoplasm of mammalian cells at the nanoscale. *Nano Lett* 11: 2157-63, 2011.
88. Kalyanaraman B, Darley-Usmar V, Davies KJ, Dennery PA, Forman HJ, Grisham MB, Mann GE, Moore K, Roberts LJ, 2nd, Ischiropoulos H. Measuring reactive oxygen and nitrogen species with fluorescent probes: challenges and limitations. *Free Radic Biol Med* 52: 1-6, 2012.

89. Kamp F, Exner N, Lutz AK, Wender N, Hegermann J, Brunner B, Nuscher B, Bartels T, Giese A, Beyer K, Eimer S, Winklhofer KF, Haass C. Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. *EMBO J* 29: 3571-89, 2010.
90. Karbowski M, Arnoult D, Chen H, Chan DC, Smith CL, Youle RJ. Quantitation of mitochondrial dynamics by photolabeling of individual organelles shows that mitochondrial fusion is blocked during the Bax activation phase of apoptosis. *J Cell Biol* 164: 493-9, 2004.
91. Karpinich NO, Tafani M, Rothman RJ, Russo MA, Farber JL. The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c. *J Biol Chem* 277: 16547-52, 2002.
92. Kasri NN, Kocks SL, Verbert L, Hebert SS, Callewaert G, Parys JB, Missiaen L, De Smedt H. Up-regulation of inositol 1,4,5-trisphosphate receptor type 1 is responsible for a decreased endoplasmic-reticulum Ca<sup>2+</sup> content in presenilin double knock-out cells. *Cell Calcium* 40: 41-51, 2006.
93. Kim CS, Jung SB, Naqvi A, Hoffman TA, DeRicco J, Yamamori T, Cole MP, Jeon BH, Irani K. p53 impairs endothelium-dependent vasomotor function through transcriptional upregulation of p66shc. *Circ Res* 103: 1441-50, 2008.
94. Klecker T, Bockler S, Westermann B. Making connections: interorganelle contacts orchestrate mitochondrial behavior. *Trends Cell Biol*, 2014.
95. Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, Ahn HJ, Ait-Mohamed O, Ait-Si-Ali S, Akematsu T, Akira S, Al-Younes HM, Al-Zeer MA, Albert ML, Albin RL, Alegre-Abarrategui J, Aleo MF, Alirezaei M, Almasan A, Almonte-Becerril M, Amano A, Amaravadi R, Amarnath S, Amer AO, Andrieu-Abadie N, Anantharam V, Ann DK, Anoopkumar-Dukie S, Aoki H, Apostolova N, Arancia G, Aris JP, Asanuma K, Asare NY, Ashida H, Askanas V, Askew DS, Auberger P, Baba M, Backues SK, Baehrecke EH, Bahr BA, Bai XY, Bailly Y, Baiocchi R, Baldini G, Balduini W, Ballabio A, Bamber BA, Bampton ET, Banhegyi G, Bartholomew CR, Bassham DC, Bast RC, Jr., Batoko H, Bay BH, Beau I, Bechet DM, Begley TJ, Behl C, Behrends C, Bekri S, Bellaire B, Bendall LJ, Benetti L, Berliocchi L, Bernardi H, Bernassola F, Besteiro S, Bhatia-Kissova I, Bi X, Biard-Piechaczyk M, Blum JS, Boise LH, Bonaldo P, Boone DL, Bornhauser BC, Bortoluci KR, Bossis I, Bost F, Bourquin JP, Boya P, Boyer-Guittaut M, Bozhkov PV, Brady NR, Brancolini C, Brech A, Brenman JE, Brennand A, Bresnick EH, Brest P, Bridges D, Bristol ML, Brookes PS, Brown EJ, Brumell JH, Brunetti-Pierri N, Brunk UT, Bulman DE, Bultman SJ, Bultynck G, Burbulla LF, Bursch W, Butchar JP, Buzgariu W, Bydlowski SP, Cadwell K, Cahova M, Cai D, Cai J, Cai Q, Calabretta B, Calvo-Garrido J, Camougrand N, Campanella M, Campos-Salinas J, Candi E, Cao L, Caplan AB, Carding SR, Cardoso SM, Carew JS, Carlin CR, Carmignac V, Carneiro LA, Carra S, Caruso RA, Casari G, Casas C, Castino R, Cebollero E, Cecconi F, Celli J, Chaachouay H, Chae HJ, Chai CY, Chan DC, Chan EY, Chang RC, Che CM, Chen CC, Chen GC, Chen GQ, Chen M, Chen Q, Chen SS, Chen W, Chen X, Chen YG, Chen Y, Chen YJ, Chen Z, Cheng A, Cheng CH, Cheng Y, Cheong H, Cheong JH, Cherry S, Chess-Williams R, Cheung ZH, Chevet E, Chiang HL, Chiarelli R, Chiba T, Chin LS, Chiou SH, Chisari FV, Cho CH, Cho DH, Choi AM, Choi D, Choi KS, Choi ME, Chouaib S, Choubey D, Choubey V, Chu CT, Chuang TH, Chueh SH, Chun T, Chwae YJ, Chye ML, Ciarcia R, Ciriolo MR, Clague MJ, Clark RS, Clarke PG, Clarke R, Codogno P, Coller HA, Colombo MI, Comincini S, Condello M,

Condorelli F, Cookson MR, Coombs GH, Coppens I, Corbalan R, Cossart P, Costelli P, Costes S, Coto-Montes A, Couve E, Coxon FP, Cregg JM, Crespo JL, Cronje MJ, Cuervo AM, Cullen JJ, Czaja MJ, D'Amelio M, Darfeuille-Michaud A, Davids LM, Davies FE, De Felici M, de Groot JF, de Haan CA, De Martino L, De Milito A, De Tata V, Debnath J, Degterev A, Dehay B, Delbridge LM, Demarchi F, Deng YZ, Dengjel J, Dent P, Denton D, Deretic V, Desai SD, Devenish RJ, Di Gioacchino M, Di Paolo G, Di Pietro C, Diaz-Araya G, Diaz-Laviada I, Diaz-Meco MT, Diaz-Nido J, Dikic I, Dinesh-Kumar SP, Ding WX, Distelhorst CW, Diwan A, Djavaheri-Mergny M, Dokudovskaya S, Dong Z, Dorsey FC, Dosenko V, Dowling JJ, Doxsey S, Dreux M, Drew ME, Duan Q, Duchosal MA, Duff K, Dugail I, Durbeej M, Duszenko M, Edelstein CL, Edinger AL, Egea G, Eichinger L, Eissa NT, Ekmekcioglu S, El-Deiry WS, Elazar Z, Elgendy M, Ellerby LM, Eng KE, Engelbrecht AM, Engelender S, Erenpreisa J, Escalante R, Esclatine A, Eskelinen EL, Espert L, Espina V, Fan H, Fan J, Fan QW, Fan Z, Fang S, Fang Y, Fanto M, Fanzani A, Farkas T, Farre JC, Faure M, Fechheimer M, Feng CG, Feng J, Feng Q, Feng Y, Fesus L, Feuer R, Figueiredo-Pereira ME, Fimia GM, Fingar DC, Finkbeiner S, Finkel T, Finley KD, Fiorito F, Fisher EA, Fisher PB, Flajolet M, Florez-McClure ML, Florio S, Fon EA, Fornai F, Fortunato F, Fotedar R, Fowler DH, Fox HS, Franco R, Frankel LB, Fransen M, Fuentes JM, Fueyo J, Fujii J, Fujisaki K, Fujita E, Fukuda M, Furukawa RH, Gaestel M, Gailly P, Gajewska M, Galliot B, Galy V, Ganesh S, Ganetzky B, Ganley IG, Gao FB, Gao GF, Gao J, Garcia L, Garcia-Manero G, Garcia-Marcos M, Garmyn M, Gartel AL, Gatti E, Gautel M, Gawriluk TR, Gegg ME, Geng J, Germain M, Gestwicki JE, Gewirtz DA, Ghavami S, Ghosh P, Giammarioli AM, Giatromanolaki AN, Gibson SB, Gilkerson RW, Ginger ML, Ginsberg HN, Golab J, Goligorsky MS, Golstein P, Gomez-Manzano C, Goncu E, Gongora C, Gonzalez CD, Gonzalez R, Gonzalez-Estevez C, Gonzalez-Polo RA, Gonzalez-Rey E, Gorbunov NV, Gorski S, Goruppi S, Gottlieb RA, Gozuacik D, Granato GE, Grant GD, Green KN, Gregorc A, Gros F, Grose C, Grunt TW, Gual P, Guan JL, Guan KL, Guichard SM, Gukovskaya AS, Gukovsky I, Gunst J, Gustafsson AB, Halayko AJ, Hale AN, Halonen SK, Hamasaki M, Han F, Han T, Hancock MK, Hansen M, Harada H, Harada M, Hardt SE, Harper JW, Harris AL, Harris J, Harris SD, Hashimoto M, Haspel JA, Hayashi S, Hazelhurst LA, He C, He YW, Hebert MJ, Heidenreich KA, Helfrich MH, Helgason GV, Henske EP, Herman B, Herman PK, Hetz C, Hilfiker S, Hill JA, Hocking LJ, Hofman P, Hofmann TG, Hohfeld J, Holyoake TL, Hong MH, Hood DA, Hotamisligil GS, Houwerzijl EJ, Hoyer-Hansen M, Hu B, Hu CA, Hu HM, Hua Y, Huang C, Huang J, Huang S, Huang WP, Huber TB, Huh WK, Hung TH, Hupp TR, Hur GM, Hurley JB, Hussain SN, Hussey PJ, Hwang JJ, Hwang S, Ichihara A, Ilkhanizadeh S, Inoki K, Into T, Iovane V, Iovanna JL, Ip NY, Isaka Y, Ishida H, Isidoro C, Isobe K, Iwasaki A, Izquierdo M, Izumi Y, Jaakkola PM, Jaattela M, Jackson GR, Jackson WT, Janji B, Jendrach M, Jeon JH, Jeung EB, Jiang H, Jiang JX, Jiang M, Jiang Q, Jiang X, Jimenez A, Jin M, Jin S, Joe CO, Johansen T, Johnson DE, Johnson GV, Jones NL, Joseph B, Joseph SK, Joubert AM, Juhasz G, Juillerat-Jeanneret L, Jung CH, Jung YK, Kaarniranta K, Kaasik A, Kabuta T, Kadowaki M, Kagedal K, Kamada Y, Kaminsky VO, Kampinga HH, Kanamori H, Kang C, Kang KB, Kang KI, Kang R, Kang YA, Kanki T, Kanneganti TD, Kanno H, Kanthasamy AG, Kanthasamy A, Karantza V, Kaushal GP, Kaushik S, Kawazoe Y, Ke PY, Kehrl JH, Kelekar A, Kerkhoff C, Kessel DH, Khalil H, Kiel JA, Kiger AA, Kihara A, Kim DR, Kim DH, Kim EK, Kim HR, Kim JS, Kim JH, Kim JC, Kim JK, Kim PK, Kim SW, Kim YS, Kim Y, Kimchi A, Kimmelman AC, King JS, Kinsella TJ, Kirkin V, Kirshenbaum LA, Kitamoto K,



Kitazato K, Klein L, Klimecki WT, Klucken J, Knecht E, Ko BC, Koch JC, Koga H, Koh JY, Koh YH, Koike M, Komatsu M, Kominami E, Kong HJ, Kong WJ, Korolchuk VI, Kotake Y, Koukourakis MI, Kouri Flores JB, Kovacs AL, Kraft C, Krainc D, Kramer H, Kretz-Remy C, Krichevsky AM, Kroemer G, Kruger R, Krut O, Ktistakis NT, Kuan CY, Kucharczyk R, Kumar A, Kumar R, Kumar S, Kundu M, Kung HJ, Kurz T, Kwon HJ, La Spada AR, Lafont F, Lamark T, Landry J, Lane JD, Lapaquette P, Laporte JF, Laszlo L, Lavandero S, Lavoie JN, Layfield R, Lazo PA, Le W, Le Cam L, Ledbetter DJ, Lee AJ, Lee BW, Lee GM, Lee J, Lee JH, Lee M, Lee MS, Lee SH, Leeuwenburgh C, Legembre P, Legouis R, Lehmann M, Lei HY, Lei QY, Leib DA, Leiro J, Lemasters JJ, Lemoine A, Lesniak MS, Lev D, Levenson VV, Levine B, Levy E, Li F, Li JL, Li L, Li S, Li W, Li XJ, Li YB, Li YP, Liang C, Liang Q, Liao YF, Liberski PP, Lieberman A, Lim HJ, Lim KL, Lim K, Lin CF, Lin FC, Lin J, Lin JD, Lin K, Lin WW, Lin WC, Lin YL, Linden R, Lingor P, Lippincott-Schwartz J, Lisanti MP, Liton PB, Liu B, Liu CF, Liu K, Liu L, Liu QA, Liu W, Liu YC, Liu Y, Lockshin RA, Lok CN, Lonial S, Loos B, Lopez-Berestein G, Lopez-Otin C, Lossi L, Lotze MT, Low P, Lu B, Lu Z, Luciano F, Lukacs NW, Lund AH, Lynch-Day MA, Ma Y, Macian F, MacKeigan JP, Macleod KF, Madeo F, Maiuri L, Maiuri MC, Malagoli D, Malicdan MC, Malorni W, Man N, Mandelkow EM, Manon S, Manov I, Mao K, Mao X, Mao Z, Marambaud P, Marazziti D, Marcel YL, Marchbank K, Marchetti P, Marciniak SJ, Marcondes M, Mardi M, Marfe G, Marino G, Markaki M, Marten MR, Martin SJ, Martinand-Mari C, Martinet W, Martinez-Vicente M, Masini M, Matarrese P, Matsuo S, Matteoni R, Mayer A, Mazure NM, McConkey DJ, McConnell MJ, McDermott C, McDonald C, McInerney GM, McKenna SL, McLaughlin B, McLean PJ, McMaster CR, McQuibban GA, Meijer AJ, Meisler MH, Melendez A, Melia TJ, Melino G, Mena MA, Menendez JA, Menna-Barreto RF, Menon MB, Menzies FM, Mercer CA, Merighi A, Merry DE, Meschini S, Meyer CG, Meyer TF, Miao CY, Miao JY, Michels PA, Michiels C, Mijaljica D, Milojkovic A, Minucci S, Miracco C, Miranti CK, Mitroulis I, Miyazawa K, Mizushima N, Mograbi B, Mohseni S, Molero X, Mollereau B, Mollinedo F, Momoi T, Monastyrska I, Monick MM, Monteiro MJ, Moore MN, Mora R, Moreau K, Moreira PI, Moriyasu Y, Moscat J, Mostowy S, Mottram JC, Motyl T, Moussa CE, Muller S, Munger K, Munz C, Murphy LO, Murphy ME, Musaro A, Mysorekar I, Nagata E, Nagata K, Nahimana A, Nair U, Nakagawa T, Nakahira K, Nakano H, Nakatogawa H, Nanjundan M, Naqvi NI, Narendra DP, Narita M, Navarro M, Nawrocki ST, Nazarko TY, Nemchenko A, Netea MG, Neufeld TP, Ney PA, Nezis IP, Nguyen HP, Nie D, Nishino I, Nislow C, Nixon RA, Noda T, Noegel AA, Nogalska A, Noguchi S, Notterpek L, Novak I, Nozaki T, Nukina N, Nurnberger T, Nyfeler B, Obara K, Oberley TD, Oddo S, Ogawa M, Ohashi T, Okamoto K, Oleinick NL, Oliver FJ, Olsen LJ, Olsson S, Opota O, Osborne TF, Ostrander GK, Otsu K, Ou JH, Ouimet M, Overholtzer M, Ozpolat B, Paganetti P, Pagnini U, Pallet N, Palmer GE, Palumbo C, Pan T, Panaretakis T, Pandey UB, Papackova Z, Papassideri I, Paris I, Park J, Park OK, Parys JB, Parzych KR, Patschan S, Patterson C, Pattingre S, Pawelek JM, Peng J, Perlmutter DH, Perrotta I, Perry G, Pervaiz S, Peter M, Peters GJ, Petersen M, Petrovski G, Phang JM, Piacentini M, Pierre P, Pierrefite-Carle V, Pierron G, Pinkas-Kramarski R, Piras A, Piri N, Plataniias LC, Poggeler S, Poirot M, Poletti A, Pous C, Pozuelo-Rubio M, Praetorius-Ibba M, Prasad A, Prescott M, Priault M, Produit-Zengaffinen N, Progulske-Fox A, Proikas-Cezanne T, Przedborski S, Przyklenk K, Puertollano R, Puyal J, Qian SB, Qin L, Qin ZH, Quaggin SE, Raben N, Rabinowich H, Rabkin SW, Rahman I, Rami A, Ramm G, Randall G, Randow

F, Rao VA, Rathmell JC, Ravikumar B, Ray SK, Reed BH, Reed JC, Reggiori F, Regnier-Vigouroux A, Reichert AS, Reiners JJ, Jr., Reiter RJ, Ren J, Revuelta JL, Rhodes CJ, Ritis K, Rizzo E, Robbins J, Roberge M, Roca H, Roccheri MC, Rocchi S, Rodemann HP, Rodriguez de Cordoba S, Rohrer B, Roninson IB, Rosen K, Rost-Roszkowska MM, Rouis M, Rouschop KM, Rovetta F, Rubin BP, Rubinsztein DC, Ruckdeschel K, Rucker EB, 3rd, Rudich A, Rudolf E, Ruiz-Opazo N, Russo R, Rusten TE, Ryan KM, Ryter SW, Sabatini DM, Sadoshima J, Saha T, Saitoh T, Sakagami H, Sakai Y, Salekdeh GH, Salomoni P, Salvaterra PM, Salvesen G, Salvioli R, Sanchez AM, Sanchez-Alcazar JA, Sanchez-Prieto R, Sandri M, Sankar U, Sansanwal P, Santambrogio L, Saran S, Sarkar S, Sarwal M, Sasakawa C, Sasnauskiene A, Sass M, Sato K, Sato M, Schapira AH, Scharl M, Schatzl HM, Scheper W, Schiaffino S, Schneider C, Schneider ME, Schneider-Stock R, Schoenlein PV, Schorderet DF, Schuller C, Schwartz GK, Scorrano L, Sealy L, Seglen PO, Segura-Aguilar J, Seiliez I, Seleverstov O, Sell C, Seo JB, Separovic D, Setaluri V, Setoguchi T, Settembre C, Shacka JJ, Shanmugam M, Shapiro IM, Shaulian E, Shaw RJ, Shelhamer JH, Shen HM, Shen WC, Sheng ZH, Shi Y, Shibuya K, Shidoji Y, Shieh JJ, Shih CM, Shimada Y, Shimizu S, Shintani T, Shirihai OS, Shore GC, Sibirny AA, Sidhu SB, Sikorska B, Silva-Zaccarin EC, Simmons A, Simon AK, Simon HU, Simone C, Simonsen A, Sinclair DA, Singh R, Sinha D, Sinicrope FA, Sirko A, Siu PM, Sivridis E, Skop V, Skulachev VP, Slack RS, Smaili SS, Smith DR, Soengas MS, Soldati T, Song X, Sood AK, Soong TW, Sotgia F, Spector SA, Spies CD, Springer W, Srinivasula SM, Stefanis L, Steffan JS, Stendel R, Stenmark H, Stephanou A, Stern ST, Sternberg C, Stork B, Stralfors P, Subauste CS, Sui X, Sulzer D, Sun J, Sun SY, Sun ZJ, Sung JJ, Suzuki K, Suzuki T, Swanson MS, Swanton C, Sweeney ST, Sy LK, Szabadkai G, Tabas I, Taegtmeier H, Tafani M, Takacs-Vellai K, Takano Y, Takegawa K, Takemura G, Takeshita F, Talbot NJ, Tan KS, Tanaka K, Tang D, Tanida I, Tannous BA, Tavernarakis N, Taylor GS, Taylor GA, Taylor JP, Terada LS, Terman A, Tettamanti G, Thevissen K, Thompson CB, Thorburn A, Thumm M, Tian F, Tian Y, Tocchini-Valentini G, Tolkovsky AM, Tomino Y, Tonges L, Tooze SA, Tournier C, Tower J, Towns R, Trajkovic V, Travassos LH, Tsai TF, Tschan MP, Tsubata T, Tsung A, Turk B, Turner LS, Tyagi SC, Uchiyama Y, Ueno T, Umekawa M, Umemiya-Shirafuji R, Unni VK, Vaccaro MI, Valente EM, Van den Berghe G, van der Klei IJ, van Doorn W, van Dyk LF, van Egmond M, van Grunsven LA, Vandenabeele P, Vandenberghe WP, Vanhorebeek I, Vaquero EC, Velasco G, Vellai T, Vicencio JM, Vierstra RD, Vila M, Vindis C, Viola G, Viscomi MT, Voitsekhovskaja OV, von Haefen C, Votruba M, Wada K, Wade-Martins R, Walker CL, Walsh CM, Walter J, Wan XB, Wang A, Wang C, Wang D, Wang F, Wang G, Wang H, Wang HG, Wang HD, Wang J, Wang K, Wang M, Wang RC, Wang X, Wang YJ, Wang Y, Wang Z, Wang ZC, Wansink DG, Ward DM, Watada H, Waters SL, Webster P, Wei L, Wehl CC, Weiss WA, Welford SM, Wen LP, Whitehouse CA, Whitton JL, Whitworth AJ, Wileman T, Wiley JW, Wilkinson S, Willbold D, Williams RL, Williamson PR, Wouters BG, Wu C, Wu DC, Wu WK, Wyttenbach A, Xavier RJ, Xi Z, Xia P, Xiao G, Xie Z, Xu DZ, Xu J, Xu L, Xu X, Yamamoto A, Yamashina S, Yamashita M, Yan X, Yanagida M, Yang DS, Yang E, Yang JM, Yang SY, Yang W, Yang WY, Yang Z, Yao MC, Yao TP, Yeganeh B, Yen WL, Yin JJ, Yin XM, Yoo OJ, Yoon G, Yoon SY, Yorimitsu T, Yoshikawa Y, Yoshimori T, Yoshimoto K, You HJ, Youle RJ, Younes A, Yu L, Yu SW, Yu WH, Yuan ZM, Yue Z, Yun CH, Yuzaki M, Zabirnyk O, Silva-Zaccarin E, Zacks D, Zacksenhaus E, Zaffaroni N, Zakeri Z, Zeh HJ, 3rd, Zeitlin SO, Zhang H, Zhang HL,

- Zhang J, Zhang JP, Zhang L, Zhang MY, Zhang XD, Zhao M, Zhao YF, Zhao Y, Zhao ZJ, Zheng X, Zhivotovsky B, Zhong Q, Zhou CZ, Zhu C, Zhu WG, Zhu XF, Zhu X, Zhu Y, Zoladek T, Zong WX, Zorzano A, Zschocke J, Zuckerbraun B. Guidelines for the use and interpretation of assays for monitoring autophagy. *Autophagy* 8: 445-544, 2012.
96. Kornmann B. The molecular hug between the ER and the mitochondria. *Curr Opin Cell Biol* 25: 443-8, 2013.
  97. Kornmann B, Currie E, Collins SR, Schuldiner M, Nunnari J, Weissman JS, Walter P. An ER-mitochondria tethering complex revealed by a synthetic biology screen. *Science* 325: 477-81, 2009.
  98. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. *Physiol Rev.* 87: 99-163, 2007.
  99. Kuwana T, Mackey MR, Perkins G, Ellisman MH, Latterich M, Schneider R, Green DR, Newmeyer DD. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. *Cell* 111: 331-42, 2002.
  100. Le S, Connors TJ, Maroney AC. c-Jun N-terminal kinase specifically phosphorylates p66ShcA at serine 36 in response to ultraviolet irradiation. *J Biol Chem* 276: 48332-6, 2001.
  101. Lebieczinska M, Duszynski J, Rizzuto R, Pinton P, Wieckowski MR. Age-related changes in levels of p66Shc and serine 36-phosphorylated p66Shc in organs and mouse tissues. *Arch Biochem Biophys* 486: 73-80, 2009.
  102. Lebieczinska M, Karkucinska-Wieckowska A, Giorgi C, Karczmarewicz E, Pronicka E, Pinton P, Duszynski J, Pronicki M, Wieckowski MR. Oxidative stress-dependent p66Shc phosphorylation in skin fibroblasts of children with mitochondrial disorders. *Biochim Biophys Acta* 1797: 952-60, 2010.
  103. Lebieczinska M, Karkucinska-Wieckowska A, Wojtala A, Suski JM, Szabadkai G, Wilczynski G, Wlodarczyk J, Diogo CV, Oliveira PJ, Tauber J, Jezek P, Pronicki M, Duszynski J, Pinton P, Wieckowski MR. Disrupted ATP synthase activity and mitochondrial hyperpolarisation-dependent oxidative stress is associated with p66Shc phosphorylation in fibroblasts of NARP patients. *Int J Biochem Cell Biol* 45: 141-50, 2013.
  104. Lebieczinska M, Szabadkai G, Jones AW, Duszynski J, Wieckowski MR. Interactions between the endoplasmic reticulum, mitochondria, plasma membrane and other subcellular organelles. *Int J Biochem Cell Biol* 41: 1805-16, 2009.
  105. Lee GS, Subramanian N, Kim AI, Aksentijevich I, Goldbach-Mansky R, Sacks DB, Germain RN, Kastner DL, Chae JJ. The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca<sup>2+</sup> and cAMP. *Nature* 492: 123-7, 2012.
  106. Lee SY, Hwang DY, Kim YK, Lee JW, Shin IC, Oh KW, Lee MK, Lim JS, Yoon DY, Hwang SJ, Hong JT. PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. *FASEB J* 20: 151-3, 2006.
  107. Lee YJ, Jeong SY, Karbowski M, Smith CL, Youle RJ. Roles of the mammalian mitochondrial fission and fusion mediators Fis1, Drp1, and Opa1 in apoptosis. *Mol Biol Cell* 15: 5001-11, 2004.
  108. Leissring MA, Parker I, LaFerla FM. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. *J Biol Chem* 274: 32535-8, 1999.

109. Li G, Mongillo M, Chin KT, Harding H, Ron D, Marks AR, Tabas I. Role of ERO1-alpha-mediated stimulation of inositol 1,4,5-triphosphate receptor activity in endoplasmic reticulum stress-induced apoptosis. *J Cell Biol* 186: 783-92, 2009.
110. Li M, Chiou KR, Kass DA. Shear stress inhibition of H<sub>2</sub>O<sub>2</sub> induced p66(Shc) phosphorylation by ASK1-JNK inactivation in endothelium. *Heart Vessels* 22: 423-7, 2007.
111. Li N, Ragheb K, Lawler G, Sturgis J, Rajwa B, Melendez JA, Robinson JP. Mitochondrial complex I inhibitor rotenone induces apoptosis through enhancing mitochondrial reactive oxygen species production. *J Biol Chem* 278: 8516-25, 2003.
112. Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential ( $\Delta\psi(m)$ ) in apoptosis; an update. *Apoptosis* 8: 115-28, 2003.
113. Marchi S, Lupini L, Patergnani S, Rimessi A, Missiroli S, Bonora M, Bononi A, Corra F, Giorgi C, De Marchi E, Poletti F, Gafa R, Lanza G, Negrini M, Rizzuto R, Pinton P. Downregulation of the mitochondrial calcium uniporter by cancer-related miR-25. *Curr Biol* 23: 58-63, 2013.
114. Marchi S, Patergnani S, Pinton P. The endoplasmic reticulum-mitochondria connection: one touch, multiple functions. *Biochim Biophys Acta* 1837: 461-9, 2014.
115. Marchi S, Pinton P. The mitochondrial calcium uniporter complex: molecular components, structure and physiopathological implications. *J Physiol* 592: 829-39, 2014.
116. Marchi S, Rimessi A, Giorgi C, Baldini C, Ferroni L, Rizzuto R, Pinton P. Akt kinase reducing endoplasmic reticulum Ca<sup>2+</sup> release protects cells from Ca<sup>2+</sup>-dependent apoptotic stimuli. *Biochem Biophys Res Commun* 375: 501-5, 2008.
117. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M, Lee WP, Weinrauch Y, Monack DM, Dixit VM. Cryopyrin activates the inflammasome in response to toxins and ATP. *Nature* 440: 228-32, 2006.
118. Marongiu R, Spencer B, Crews L, Adame A, Patrick C, Trejo M, Dallapiccola B, Valente EM, Masliah E. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. *J Neurochem* 108: 1561-74, 2009.
119. Martin LJ, Pan Y, Price AC, Sterling W, Copeland NG, Jenkins NA, Price DL, Lee MK. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. *J Neurosci* 26: 41-50, 2006.
120. May D, Itin A, Gal O, Kalinski H, Feinstein E, Keshet E. Ero1-L alpha plays a key role in a HIF-1-mediated pathway to improve disulfide bond formation and VEGF secretion under hypoxia: implication for cancer. *Oncogene* 24: 1011-20, 2005.
121. Migliaccio E, Giorgio M, Pelicci PG. Apoptosis and aging: role of p66Shc redox protein. *Antioxid Redox Signal* 8: 600-8, 2006.
122. Migliaccio E, Mele S, Salcini AE, Pelicci G, Lai KM, Superti-Furga G, Pawson T, Di Fiore PP, Lanfrancone L, Pelicci PG. Opposite effects of the p52shc/p46shc and p66shc splicing isoforms on the EGF receptor-MAP kinase-fos signalling pathway. *EMBO J* 16: 706-16, 1997.
123. Murakami T, Ockinger J, Yu J, Byles V, McColl A, Hofer AM, Horng T. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. *Proc Natl Acad Sci U S A* 109: 11282-7, 2012.

124. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW, Choi AM. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. *Nat Immunol* 12: 222-30, 2011.
125. Naon D, Scorrano L. At the right distance: ER-mitochondria juxtaposition in cell life and death. *Biochim Biophys Acta*, 2014.
126. Napoli C, Martin-Padura I, de Nigris F, Giorgio M, Mansueto G, Somma P, Condorelli M, Sica G, De Rosa G, Pelicci P. Deletion of the p66Shc longevity gene reduces systemic and tissue oxidative stress, vascular cell apoptosis, and early atherogenesis in mice fed a high-fat diet. *Proc Natl Acad Sci U S A* 100: 2112-6, 2003.
127. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. *J Cell Biol* 183: 795-803, 2008.
128. Nauseef WM. Detection of superoxide anion and hydrogen peroxide production by cellular NADPH oxidases. *Biochim Biophys Acta* 1840: 757-67, 2014.
129. Nemoto S, Combs CA, French S, Ahn BH, Fergusson MM, Balaban RS, Finkel T. The mammalian longevity-associated gene product p66shc regulates mitochondrial metabolism. *J Biol Chem* 281: 10555-60, 2006.
130. Oelze M, Kroller-Schon S, Steven S, Lubos E, Doppler C, Hausding M, Tobias S, Brochhausen C, Li H, Torzewski M, Wenzel P, Bachschmid M, Lackner KJ, Schulz E, Munzel T, Daiber A. Glutathione peroxidase-1 deficiency potentiates dysregulatory modifications of endothelial nitric oxide synthase and vascular dysfunction in aging. *Hypertension* 63: 390-6, 2014.
131. Okada S, Kao AW, Ceresa BP, Blaikie P, Margolis B, Pessin JE. The 66-kDa Shc isoform is a negative regulator of the epidermal growth factor-stimulated mitogen-activated protein kinase pathway. *J Biol Chem* 272: 28042-9, 1997.
132. Olichon A, Baricault L, Gas N, Guillou E, Valette A, Belenguer P, Lenaers G. Loss of OPA1 perturbs the mitochondrial inner membrane structure and integrity, leading to cytochrome c release and apoptosis. *J Biol Chem* 278: 7743-6, 2003.
133. Orsini F, Migliaccio E, Moroni M, Contursi C, Raker VA, Piccini D, Martin-Padura I, Pelliccia G, Trinei M, Bono M, Puri C, Tacchetti C, Ferrini M, Mannucci R, Nicoletti I, Lanfrancone L, Giorgio M, Pelicci PG. The life span determinant p66Shc localizes to mitochondria where it associates with mitochondrial heat shock protein 70 and regulates trans-membrane potential. *J Biol Chem* 279: 25689-95, 2004.
134. Osowski CM, Hara T, O'Sullivan-Murphy B, Kanekura K, Lu S, Hara M, Ishigaki S, Zhu LJ, Hayashi E, Hui ST, Greiner D, Kaufman RJ, Bortell R, Urano F. Thioredoxin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. *Cell Metab* 16: 265-73, 2012.
135. Ottolini D, Cali T, Negro A, Brini M. The Parkinson disease-related protein DJ-1 counteracts mitochondrial impairment induced by the tumour suppressor protein p53 by enhancing endoplasmic reticulum-mitochondria tethering. *Hum Mol Genet* 22: 2152-68, 2013.
136. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. *Nat Neurosci* 5: 731-6, 2002.

137. Papanicolaou KN, Khairallah RJ, Ngoh GA, Chikando A, Luptak I, O'Shea KM, Riley DD, Lugus JJ, Colucci WS, Lederer WJ, Stanley WC, Walsh K. Mitofusin-2 maintains mitochondrial structure and contributes to stress-induced permeability transition in cardiac myocytes. *Mol Cell Biol* 31: 1309-28, 2011.
138. Paradies G, Petrosillo G, Paradies V, Ruggiero FM. Role of cardiolipin peroxidation and Ca<sup>2+</sup> in mitochondrial dysfunction and disease. *Cell Calcium* 45: 643-50, 2009.
139. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. *Nature* 441: 1157-1161, 2006.
140. Park S, Juliana C, Hong S, Datta P, Hwang I, Fernandes-Alnemri T, Yu JW, Alnemri ES. The mitochondrial antiviral protein MAVS associates with NLRP3 and regulates its inflammasome activity. *J Immunol* 191: 4358-66, 2013.
141. Patergnani S, Marchi S, Rimessi A, Bonora M, Giorgi C, Mehta KD, Pinton P. PRKCB/protein kinase C, beta and the mitochondrial axis as key regulators of autophagy. *Autophagy* 9: 1367-85, 2013.
142. Patergnani S, Suski JM, Agnoletto C, Bononi A, Bonora M, De Marchi E, Giorgi C, Marchi S, Missiroli S, Poletti F, Rimessi A, Duszynski J, Wieckowski MR, Pinton P. Calcium signaling around Mitochondria Associated Membranes (MAMs). *Cell Commun Signal* 9: 19, 2011.
143. Petrosillo G, Colantuono G, Moro N, Ruggiero FM, Tiravanti E, Di Venosa N, Fiore T, Paradies G. Melatonin protects against heart ischemia-reperfusion injury by inhibiting mitochondrial permeability transition pore opening. *Am J Physiol Heart Circ Physiol* 297: H1487-93, 2009.
144. Pinton P, Giorgi C, Pandolfi PP. The role of PML in the control of apoptotic cell fate: a new key player at ER-mitochondria sites. *Cell Death Differ* 18: 1450-6, 2011.
145. Pinton P, Giorgi C, Siviero R, Zecchini E, Rizzuto R. Calcium and apoptosis: ER-mitochondria Ca<sup>2+</sup> transfer in the control of apoptosis. *Oncogene* 27: 6407-18, 2008.
146. Pinton P, Rimessi A, Marchi S, Orsini F, Migliaccio E, Giorgio M, Contursi C, Minucci S, Mantovani F, Wieckowski MR, Del Sal G, Pelicci PG, Rizzuto R. Protein kinase C beta and prolyl isomerase 1 regulate mitochondrial effects of the life-span determinant p66Shc. *Science* 315: 659-63, 2007.
147. Poston CN, Krishnan SC, Bazemore-Walker CR. In-depth proteomic analysis of mammalian mitochondria-associated membranes (MAM). *J Proteomics* 79: 219-30, 2013.
148. Prause J, Goswami A, Katona I, Roos A, Schnizler M, Bushuven E, Dreier A, Buchkremer S, Johann S, Beyer C, Deschauer M, Troost D, Weis J. Altered localization, abnormal modification and loss of function of Sigma receptor-1 in amyotrophic lateral sclerosis. *Hum Mol Genet* 22: 1581-600, 2013.
149. Raturi A, Simmen T. Where the endoplasmic reticulum and the mitochondrion tie the knot: the mitochondria-associated membrane (MAM). *Biochim Biophys Acta* 1833: 213-24, 2013.
150. Reboredo M, Greaves RF, Hahn G. Human cytomegalovirus proteins encoded by UL37 exon 1 protect infected fibroblasts against virus-induced apoptosis and are required for efficient virus replication. *J Gen Virol* 85: 3555-67, 2004.
151. Redmann M, Dodson M, Boyer-Guittaut M, Darley-Usmar V, Zhang J. Mitophagy mechanisms and role in human diseases. *Int J Biochem Cell Biol* 53: 127-33, 2014.

152. Reichert AS, Neupert W. Contact sites between the outer and inner membrane of mitochondria-role in protein transport. *Biochim Biophys Acta* 1592: 41-9, 2002.
153. Rimessi A, Marchi S, Patergnani S, Pinton P. H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling. *Oncogene* 33: 2329-40, 2014.
154. Rizzuto R, Pinton P, Carrington W, Fay FS, Fogarty KE, Lifshitz LM, Tuft RA, Pozzan T. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca<sup>2+</sup> responses. *Science* 280: 1763-6, 1998.
155. Rossol M, Pierer M, Raulien N, Quandt D, Meusch U, Rothe K, Schubert K, Schoneberg T, Schaefer M, Krugel U, Smajilovic S, Brauner-Osborne H, Baerwald C, Wagner U. Extracellular Ca<sup>2+</sup> is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors. *Nat Commun* 3: 1329, 2012.
156. Sano R, Annunziata I, Patterson A, Moshiach S, Gomero E, Opferman J, Forte M, d'Azzo A. GM1-ganglioside accumulation at the mitochondria-associated ER membranes links ER stress to Ca(2+)-dependent mitochondrial apoptosis. *Mol Cell* 36: 500-11, 2009.
157. Saxena G, Chen J, Shalev A. Intracellular shuttling and mitochondrial function of thioredoxin-interacting protein. *J Biol Chem* 285: 3997-4005, 2010.
158. Schon EA, Area-Gomez E. Mitochondria-associated ER membranes in Alzheimer disease. *Mol Cell Neurosci* 55: 26-36, 2013.
159. Schroder K, Tschopp J. The inflammasomes. *Cell* 140: 821-32, 2010.
160. Seth RB, Sun L, Ea CK, Chen ZJ. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. *Cell* 122: 669-82, 2005.
161. Shavali S, Brown-Borg HM, Ebadi M, Porter J. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. *Neurosci Lett* 439: 125-8, 2008.
162. Shimizu S, Matsuoka Y, Shinohara Y, Yoneda Y, Tsujimoto Y. Essential role of voltage-dependent anion channel in various forms of apoptosis in mammalian cells. *J Cell Biol* 152: 237-50, 2001.
163. Sies H. Role of metabolic H<sub>2</sub>O<sub>2</sub> generation: redox signaling and oxidative stress. *J Biol Chem* 289: 8735-41, 2014.
164. Simmen T, Aslan JE, Blagoveshchenskaya AD, Thomas L, Wan L, Xiang Y, Feliciangeli SF, Hung CH, Crump CM, Thomas G. PACS-2 controls endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis. *EMBO J* 24: 717-29, 2005.
165. Simmen T, Lynes EM, Gesson K, Thomas G. Oxidative protein folding in the endoplasmic reticulum: tight links to the mitochondria-associated membrane (MAM). *Biochim Biophys Acta* 1798: 1465-73, 2010.
166. Spescha RD, Glanzmann M, Simic B, Witassek F, Keller S, Akhmedov A, Tanner FC, Luscher TF, Camici GG. Adaptor protein p66(Shc) mediates hypertension-associated, cyclic stretch-dependent, endothelial damage. *Hypertension* 64: 347-53, 2014.
167. Subramanian N, Natarajan K, Clatworthy MR, Wang Z, Germain RN. The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. *Cell* 153: 348-61, 2013.

168. Suski JM, Lebiedzinska M, Wojtala A, Duszynski J, Giorgi C, Pinton P, Wieckowski MR. Isolation of plasma membrane-associated membranes from rat liver. *Nat Protoc* 9: 312-22, 2014.
169. Szalai G, Krishnamurthy R, Hajnoczky G. Apoptosis driven by IP(3)-linked mitochondrial calcium signals. *EMBO J* 18: 6349-61, 1999.
170. Trinei M, Giorgio M, Cicalese A, Barozzi S, Ventura A, Migliaccio E, Milia E, Padura IM, Raker VA, Maccarana M, Petronilli V, Minucci S, Bernardi P, Lanfrancone L, Pelicci PG. A p53-p66Shc signalling pathway controls intracellular redox status, levels of oxidation-damaged DNA and oxidative stress-induced apoptosis. *Oncogene* 21: 3872-8, 2002.
171. Tschopp J. Mitochondria: Sovereign of inflammation? *Eur J Immunol* 41: 1196-202, 2011.
172. Tu BP, Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. *J Cell Biol* 164: 341-6, 2004.
173. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De Strooper B, Yu G, Bezprozvanny I. Presenilins form ER Ca<sup>2+</sup> leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. *Cell* 126: 981-93, 2006.
174. Verfaillie T, Rubio N, Garg AD, Bultynck G, Rizzuto R, Decuyper JP, Piette J, Linehan C, Gupta S, Samali A, Agostinis P. PERK is required at the ER-mitochondrial contact sites to convey apoptosis after ROS-based ER stress. *Cell Death Differ* 19: 1880-91, 2012.
175. Wang X, Winter D, Ashrafi G, Schlehe J, Wong YL, Selkoe D, Rice S, Steen J, LaVoie MJ, Schwarz TL. PINK1 and Parkin target Miro for phosphorylation and degradation to arrest mitochondrial motility. *Cell* 147: 893-906, 2011.
176. Wardman P. Fluorescent and luminescent probes for measurement of oxidative and nitrosative species in cells and tissues: progress, pitfalls, and prospects. *Free Radic Biol Med* 43: 995-1022, 2007.
177. Wasiak S, Zunino R, McBride HM. Bax/Bak promote sumoylation of DRP1 and its stable association with mitochondria during apoptotic cell death. *J Cell Biol* 177: 439-50, 2007.
178. Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S, Karbach SH, Schwenk M, Yogev N, Schulz E, Oelze M, Grabbe S, Jonuleit H, Becker C, Daiber A, Waisman A, Munzel T. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. *Circulation* 124: 1370-81, 2011.
179. Wieckowski MR, Giorgi C, Lebiedzinska M, Duszynski J, Pinton P. Isolation of mitochondria-associated membranes and mitochondria from animal tissues and cells. *Nat Protoc* 4: 1582-90, 2009.
180. Wiley SE, Andreyev AY, Divakaruni AS, Karisch R, Perkins G, Wall EA, van der Geer P, Chen YF, Tsai TF, Simon MI, Neel BG, Dixon JE, Murphy AN. Wolfram Syndrome protein, Miner1, regulates sulphhydryl redox status, the unfolded protein response, and Ca<sup>2+</sup> homeostasis. *EMBO Mol Med* 5: 904-18, 2013.
181. Winterbourn CC. The challenges of using fluorescent probes to detect and quantify specific reactive oxygen species in living cells. *Biochim Biophys Acta* 1840: 730-8, 2014.



182. Winther JR, Thorpe C. Quantification of thiols and disulfides. *Biochim Biophys Acta* 1840: 838-46, 2014.
183. Wood-Kaczmar A, Gandhi S, Yao Z, Abramov AY, Miljan EA, Keen G, Stanyer L, Hargreaves I, Klupsch K, Deas E, Downward J, Mansfield L, Jat P, Taylor J, Heales S, Duchon MR, Latchman D, Tabrizi SJ, Wood NW. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. *PLoS One* 3: e2455, 2008.
184. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H, Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of *Drosophila* Pink1 is rescued by Parkin. *Proc Natl Acad Sci U S A* 103: 10793-8, 2006.
185. Yu W, Sun Y, Guo S, Lu B. The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. *Hum Mol Genet* 20: 3227-40, 2011.
186. Zaid H, Abu-Hamad S, Israelson A, Nathan I, Shoshan-Barmatz V. The voltage-dependent anion channel-1 modulates apoptotic cell death. *Cell Death.Differ.* 12: 751-760, 2005.
187. Zatti G, Ghidoni R, Barbiero L, Binetti G, Pozzan T, Fasolato C, Pizzo P. The presenilin 2 M239I mutation associated with familial Alzheimer's disease reduces Ca<sup>2+</sup> release from intracellular stores. *Neurobiol Dis* 15: 269-78, 2004.
188. Zhang A, Williamson CD, Wong DS, Bullough MD, Brown KJ, Hathout Y, Colberg-Poley AM. Quantitative proteomic analyses of human cytomegalovirus-induced restructuring of endoplasmic reticulum-mitochondrial contacts at late times of infection. *Mol Cell Proteomics* 10: M111 009936, 2011.
189. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin-interacting protein links oxidative stress to inflammasome activation. *Nat Immunol* 11: 136-40, 2010.
190. Zhou R, Yazdi AS, Menu P, Tschopp J. A role for mitochondria in NLRP3 inflammasome activation. *Nature* 469: 221-5, 2011.

## FIGURE LEGENDS:

**Fig. 1 – TEM imaging of MAMs.** Representative transmission electron micrographs of mitochondria, ER and MAMs in mouse embryonic fibroblasts (original magnification, 70,000x). The middle and right panels show a magnification of the selected area.

**Fig. 2 – Determination of MAMs via fluorescence microscopy.** HeLa cells were transfected with the SEC61-GFP plasmid to label the ER (green) and loaded with MitoTracker Deep Red to visualize the mitochondrial compartment (red). In the merged and zoomed images, the white areas correspond to the MAMs. Images were obtained using a confocal laser scanning microscope at 63x magnification.

**Fig. 3 – A summary of the MAM-enriched proteins involved in ROS production.** During hypoxic condition, the ER-MAM-resident proteins Ero1- $\alpha$  and ERp44 interact and modulate ER-mitochondria  $\text{Ca}^{2+}$  communication. In addition, elevated levels of Ero1- $\alpha$  may promote activation of the UPR-system with consequent increase in ROS production and  $\text{Ca}^{2+}$  release from ER. Another MAM protein, p66SHC, is activated under oxidative stress. In parallel, p66Shc can translocate to the mitochondria, where it participates in ROS formation. Abbreviations: ERK: extracellular-signal-regulated kinase, JNK: Jun amino-terminal kinases, PP2A: protein phosphatase 2A, Pin1: peptidyl-prolyl cis/trans isomerase, ROS: reactive oxygen species, cyt.c: cytochrome c, Ero1 $\alpha$ : oxireductase endoplasmic reticulum oxidoreductin-1 alpha, ERP44: endoplasmic reticulum resident protein 44; UPR: unfolded protein response.

**Fig. 4 – A schematic overview of the main MAM-associated proteins involved in apoptosis.** A growing body of evidence highlights the importance of several MAM-related proteins in the regulation of the apoptotic pathway. Some of these proteins can modulate apoptosis through the generation of ROS, formation of cardiolipin (CL) microdomains or recruitment and regulation of fission/fusion proteins.

Other proteins that link the ER to the mitochondrial surface (particularly PML, AKT, PTEN and RAS) are able to modulate the execution of apoptosis by controlling  $Ca^{2+}$  waves in stressed cells. As a result, excess  $Ca^{2+}$  flowing out of the ER is taken up by the mitochondria (through the uniporter complex), promoting the execution of the apoptotic program. Abbreviations: DRP1: dynamin-related protein 1, MFN2: mitofusin 2, PACS2: phosphofurin acidic cluster sorting protein 2, PERK1: protein kinase RNA-like endoplasmic reticulum kinase IRE1-a: inositol-requiring kinase 1, ATF6: activating transcription factor 6, FIS1: fission 1 (mitochondrial outer membrane) homolog (*S. cerevisiae*), BAP31: mammalian B-cell receptor-associated protein 31, HK2: hexokinase2, cyPd: Cyclophilin-D, PP2A: Protein phosphatase 2A, ERO1-a: oxidoreductase endoplasmic reticulum oxidoreductin-1 alpha, ERP44: endoplasmic reticulum resident protein 44.

**Fig. 5 – The importance of ER-mitochondria contact sites in autophagy induction and execution.** Although the biogenesis of the autophagosome is complex and incompletely understood, it has been demonstrated that MAMs contribute to the initiation of the isolation membrane of the autophagosome. For example, several autophagy-related proteins reside in MAM compartments, and MAM proteins are also critical regulators of the execution of the autophagic machinery. For instance, upon activation

by PKC  $\beta$  (protein kinase C-  $\beta$ ), the MAM protein p66Shc promotes autophagy. Furthermore, a recent study highlighting the critical role of mitochondria in supplying membrane material during the mitophagic mechanism could open new avenues for the investigation of novel roles of MAMs in the regulation of the molecular pathway of selective autophagy. Abbreviations: ATG: autophagy-related, DFCEP1: double FYVE domain-containing protein 1, Rab32: small GTP-binding protein 32 of the RAB family, PINK1: PTEN-induced putative kinase 1

**Fig. 6 – Schematic representation of the complex ER-mitochondria connections in the coordination of inflammasome formation.** In the presence of pro-inflammatory stimuli, NLRP3 translocates to MAMs with ASC and pro-caspase1, inducing caspase-1 activation and the production of IL-1  $\beta$  and IL-18. Increased levels of ROS and activation of the UPR-system via ER-stress are essential for NLRP3 activation. MAVS is located at the outer mitochondrial membrane and mediates antiviral signaling. Abbreviations: ASC: apoptosis-associated speck-like protein containing a caspase recruitment domain; MAVS: mitochondria-associated viral sensor; NLRP3: NOD-like receptor family 3; ROS: reactive oxygen species; UPR: unfolded protein response.

**Fig. 7 – Involvement of the ER-mitochondria interface in the pathogenesis of neuronal disorders such as Alzheimer's Disease (AD) and Parkinson's Disease (PD).** Alterations of Ca<sup>2+</sup> homeostasis represent a link between MAMs and neuronal diseases, particularly concerning the alterations of Ca<sup>2+</sup> crosstalk between the ER and mitochondria at the MAMs. A  $\beta$  oligomers affect mitochondrial functionality by enhancing

ER  $\text{Ca}^{2+}$  and facilitate the opening of the PTP.  $\alpha$ -synuclein positively affects  $\text{Ca}^{2+}$  transfer from the ER to the mitochondria. Abbreviations: A  $\beta$ : amyloid-beta; cyt C: cytochrome C; PSs: presenilins

**Fig. 8 – Schematic representation of the ER-mitochondria interface in Huntington’s Disease (HD), amyotrophic lateral sclerosis (ALS) and Wolfram Syndrome.**

In HD, mutant HTT increases ER  $\text{Ca}^{2+}$  release by acting on  $\text{InsP}_3\text{R}$ . Mutant VAPB enhances ER-mitochondria tethering in ALS; Sig1R has also been proposed to be involved in the pathogenesis of ALS. Miner1, a protein that, when mutated, causes Wolfram Syndrome, is enriched at MAMs. Abbreviations: HAP-1A: huntingtin-associated protein 1-A; mutHTT: mutant huntingtin, PTPIP51: protein tyrosine phosphatase-interacting protein 51; VAPB: vesicle-associated membrane protein-associated protein B.

**Fig. 9 – An illustrated overview of the main functions attributed to MAMs.** Correct homeostasis of MAMs is a key determinant of several cellular processes. For example, the activities of several MAM proteins have been found to be corrupted during the pathogenesis of a number of human diseases.

## **ABBREVIATIONS USED:**

A  $\beta$  = amyloid-  $\beta$

AD= Alzheimer's disease

ASC =apoptosis-associated speck-like protein containing a caspase recruitment domain

ASK1= apoptosis signal-regulating kinase 1

CaSR= murine calcium-sensing receptor

CL= cardiolipin

CNX= calnexin

DRP1= dynamin-related protein 1

ER= endoplasmic reticulum

ERAD= ER-associated degradation

ERK= extracellular signal-regulated kinase

ERMES= ER-mitochondria encounter structure

ERp44= endoplasmic reticulum resident protein 44

FAD= familial Alzheimer's disease

FATP4= fatty acid transport protein 4

GM1= GM1- ganglioside

GRP75= glucose-regulated protein 75-kDa

HIV-1= human immunodeficiency virus type 1

JNK= c-Jun N-terminal kinase

IMM= inner mitochondrial membrane

IMS= mitochondrial intermembrane space

IP3R= inositol 1,4,5-trisphosphate receptor


MAMs= mitochondria associated membranes  
MAVS= mitochondrial antiviral signaling protein  
MCU= mitochondrial calcium uniporter  
MDA5= melanoma differentiation-associated gene 5  
MMP= mitochondrial outer membrane permeabilization  
mPTP= mitochondrial permeability transition pore  
OMM= outer mitochondrial membrane  
PACS-2= phosphofurin acidic cluster sorting protein 2  
PAMs= plasma membranes associated membranes  
PD= Parkinson's disease  
PDI= protein disulfide-isomerase  
PEMT2= phosphatidylethanolamine N-methyltransferase 2  
PKC  $\beta$  = protein kinase C  $\beta$   
PML= promyelocytic leukemia protein  
PP2A= phosphatase A2  
PS1= presenilin-1  
PS2= presenilin-2  
SERAC1= serine active site containing 1  
SIG1R= sigma-1 receptor  
STING= STimulator of INterferon Genes  
TXNIP= thioredoxin interacting protein  
VAPB= Vesicle-associated membrane protein-associated protein B  
VDAC= voltage-dependent anion channel

Vpr= viral protein R


$\Psi_m$ = the mitochondrial membrane potential




Giorgi Fig.1




Giorgi Fig.2




Giorgi Fig. 3




Giorgi Fig.4




Giorgi Fig.5




Giorgi Fig.6



Giorgi Fig.7



Giorgi Fig.8





Giorgi Fig.9

